¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡GÀ³³\¤§¦a10141362 |
µoªí®É¶¡:2023/3/30 ¤U¤È 01:14:02
²Ä 1749 ½g¦^À³
|
§Aı±o¦³±Ï´N¦³±Ï¡AÃø¹D§Ú¸ò§A»¡¨S±Ï§A´N½æªÑ²¼¶Ü¡H ¥ÎÔ£»ù¦ì½æµ¹½Ö¡H¦p¦ó¥æ³Î¡H |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¶À¥ý¥Í10132784 |
µoªí®É¶¡:2023/3/24 ¤U¤È 01:13:03
²Ä 1748 ½g¦^À³
|
½Ð±Ð¦U¦ì¤j¤j³o¤äªÑ²¼ÁÙ¦³±Ï¶Ü?ÁÙ¯à¯d¶Ü?¤UÂd§Ö¹O3Ó¤ë,¦AµL»²¾É¨é°Ó,¤W¿³Âd¥ÃµL±æ,ÁٽЦU¦ì¤j¤j«üÂI°g¬z |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¾å¦à10141996 |
µoªí®É¶¡:2023/3/20 ¤W¤È 09:49:59
²Ä 1747 ½g¦^À³
|
³o¦¸²{¼W¡An¶Ò¸ê3»õ¡A©~µM¥u¶Ò¨ì1.418»õ¡A³s¤@¥b³£¤£¨ì¡C 10¤¸¤@ªÑ¨S¤H»{ÁÊ¡A¤jªÑªF¤]¤£´±±µ¡A½²¸³¹ï¥~ªº credibility ¥i¥H»¡.......¡C ¤W¿³Âd¥H¨Ó¨º»ò¦h¦~¼ö±¡¤ä«ùªºªÑªFÌ¡A¯u¥¿¤W¤FÄ_¶Qªº¤@½Ò ¡I |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡GABC10134671 |
µoªí®É¶¡:2023/2/20 ¤U¤È 05:24:57
²Ä 1746 ½g¦^À³
|
¤½§i¥»¤½¥q©µªø111¦~²Ä¤G¦¸²{ª÷¼W¸ê¯S©w¤Hú´Ú´Á¶¡ ¨Æ¹êµo¥Í¤é 112/02/20 »¡©ú 1.¨Æ¹êµo¥Í¤é:112/02/20 2.µo¥Í½t¥Ñ: ìq¯S©w¤Hú´Ú´Á¬°112¦~02¤ë23¤é¡A¬°¦]À³¯S©w¤H°Ñ»P¥»¦¸²{ª÷¼W¸ê§@·~¥¼¯à ©óú´Ú´Á¤º¤Î®É§¹¦¨¡AÀÀ©µªø111¦~²Ä¤G¦¸²{ª÷¼W¸ê¯S©w¤Hú´Ú´Á¶¡¡C 3.¦]À³±¹¬I: ¥»¦¸²{ª÷¼W¸ê¨Ì¾Ú¥»¤½¥q111¦~12¤ë23¤é¸³¨Æ·|¨Mij¡A±ÂÅv¸³¨Æªøµø¤½¥q¹ê»Ú »Ýn¥þÅv¿ì²z×¥¿©Î½Õ¾ã¡A¨Ã©ó112¦~01¤ë10¤é¸gª÷ºÞ·|ÃÒ´Á§½ª÷ºÞÃÒµo¦r²Ä¡@ 1110368129¸¹¨ç®Öã¥Í®Ä¦b®×¡C ¸g¸³¨Æªø®Ö¨M¡Aì¯S©w¤HªÑ´Úú¯Ç´Á¶¡¦Û112¦~02¤ë21¤é°_¦Ü112¦~02¤ë23¤é¤î¡A ½Õ¾ã¬°¦Û112¦~02¤ë21¤é°_¦Ü112¦~04¤ë10¤é¤î¡C 4.¨ä¥LÀ³±Ô©ú¨Æ¶µ:²{ª÷¼W¸ê°ò·Ç¤é¡A«Ý¹ê»ÚªÑ´Ú¶Ò¨¬«á±ÂÅv¸³¨Æªøq©w¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡Gjimmylin10141563 |
µoªí®É¶¡:2023/2/18 ¤W¤È 11:55:33
²Ä 1745 ½g¦^À³
|
§Ö¥h°Ý½²¸³n¤£n»{¦Û¤vªº¼W¸êªÑ§a? XD §O¦Ñ¼L¬Æ»òì©lªÑªF¥»¨Ó´N¨S¦b»{¼W¸êªÑ¡A§A¤ß®®²{¦b³o®É¨è¬O«Ü¦³©³®ð³á? 40 24 ³£¨S¼W¸ê¦¨¥\¡A½²¸³³o¦¸¼W¸ê°O±o®i²{¦Û¤vªº¹ê¤O©M¨M¤ß¡A¤~¤£·|Åý½²¯»¥¢±æ°Ú! (§O¤Hªº¿ú¤£¬O¿ú¡A¦Û¤vªº¿ú´NÃø»¡¤F¡A«¢«¢«¢!) »{¦Prabbit©Ò¨¥
ÁöµM§Ú¤]®M¤F¤@§¾ªÑ ¤£n¦Aºq¥\¹|¼w ¬Ý~
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡Grabbit10136567 |
µoªí®É¶¡:2023/2/18 ¤W¤È 11:43:55
²Ä 1744 ½g¦^À³
|
¨S²¼¶W²nªº¡A½æ±¼ªº¸êª÷¦sµÛ©ñ§O³B´N¬Onµ¥½²¸³¤U¥x¤~n¨Ó§ë¸ê¡A¶W²nªº¡A¨S²¼´N¬O²n XD ½²¸³¤£¤U¥x¡Aªü³»¦h´N¤£§ë¸ê¤ß®®¦Ó¤w¡A¶W²nªº XD
¨Ó³o¬O¸ò½²¯»²á¤Ñ¡A¤~¨SÃö¤ß¦³½²¸³ªº¤ß®®¡A°·±d¹«~¦³®Öã¦r¸¹ªº¦hªº¬O¡A¤ß®®? ¦^µª¤£¥X¨Ó´NÂಾ¸ÜÃD¬O«ç¼Ë? XD
¤£¹L§Ú¦V¨Ó³ßÅw½²¯»¡A§Ú¨Ó¬°§AÌ¥´¥´®ð: «Ø±d¹«~¥²ºÙ¤ý ¼W¸ê¤£¶¶½²¸³¦ª
§Ö¥h°Ý½²¸³n¤£n»{¦Û¤vªº¼W¸êªÑ§a? XD §O¦Ñ¼L¬Æ»òì©lªÑªF¥»¨Ó´N¨S¦b»{¼W¸êªÑ¡A§A¤ß®®²{¦b³o®É¨è¬O«Ü¦³©³®ð³á? 40 24 ³£¨S¼W¸ê¦¨¥\¡A½²¸³³o¦¸¼W¸ê°O±o®i²{¦Û¤vªº¹ê¤O©M¨M¤ß¡A¤~¤£·|Åý½²¯»¥¢±æ°Ú! (§O¤Hªº¿ú¤£¬O¿ú¡A¦Û¤vªº¿ú´NÃø»¡¤F¡A«¢«¢«¢!)
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡Gªü¤Ñ10149120 |
µoªí®É¶¡:2023/2/17 ¤U¤È 10:49:52
²Ä 1743 ½g¦^À³
|
©_©Ç¤F¡A½æ¤FªÑ²¼¤â¤¤¨S¤ß®®ªº¤H·F¹À¤@ª½¦^¨ÓÃö¤ß¡H ®æ§½¤j¤@ÂI¡A¥hÃö¤ß¨ä¥L§óȱoÃö¤ßªºªÑ²¼¤£¬O§ó¦n¡H ¤£Â_ªº°Û°I¡A¤p¤ß§AªººÖ³ø¤]¦bºCºC´î·l³á¡I ªp¥B¦b³o°Û°I¬O¯àÅý§AÁȦ^¨Ó¶Ü¡H |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡Gfantasize10140160 |
µoªí®É¶¡:2023/2/17 ¤U¤È 08:36:57
²Ä 1742 ½g¦^À³
|
§A·|·Q¶R¡A³o¥O§Ú·P¨ìµL¤ñªºªY¼¢¡C
½²¸³¬°Ãöª`¤HÃþªº°·±d¦Ó§V¤O¥I¥X¡A¦¨´N«D¤Z¤D¥xÆW¤§¥ú¡K
§AÀ³¸Ó¤]¦Ñ¤j¤£¤p¤F§a¡A½Ð@¤ßµ¥«Ý¡A¤£n³o»òµU«æ¹À¡I
¬Ý¨ì¤ß®®¤U¶^¡AÅå·W¥¢±¹¡B¸U¤À´q®£¡B¤£ÅU¤@¤Á§â¤ß®®½æ¦b¦n¯ºªº»ù®æ¡A¥¢¥h¤F¼W¸êªº¸ê®æ¡A²×¤é¥H²\¬~Áy¡BÆ{Æ{¹èÅw¡K³o¤£¤]¬O¦]¬°µU«æªº©Ê¤l¨ÏµM¡H
¨S¦³Ãö«Y¡A§Æ±æ½²¸³¯àÀ°§U¨ì§A¡A¤]¯àÀ°§U¥@¬É¤W»ÝnÀ°§Uªº¨C¤@Ó¤H¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G²q·Q10148412 |
µoªí®É¶¡:2023/2/17 ¤U¤È 06:41:56
²Ä 1741 ½g¦^À³
|
ì¨Ó¤j®a¦b°Q½×³o«h·s»D
·s»D tw.stock.yahoo.com/news/%E5%BF%83%E6%82%85%E5%89%B5%E6%96%B0%E6%9B%BF%E4%BB%A3%E7%99%82%E6%B3%95-%E6%8F%90%E4%BE%9B%E4%BA%9E%E5%81%A5%E5%BA%B7%E8%80%85%E7%85%A7%E8%AD%B7%E6%9C%8D%E5%8B%99-180832893.html
¼v¤ù www.youtube.com/watch?v=rqdYkHqyW_A |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡Grabbit10136567 |
µoªí®É¶¡:2023/2/17 ¤U¤È 06:41:39
²Ä 1740 ½g¦^À³
|
«Øij§A§â¤ß®®½æ±¼ªº¿ú¡A®³¥h¶R®®¤ß´¼¡B®®¤ß¼Ö¡C ¬O§AÁ¿ªºªü¡A©Ò¥H§Ú·Q¶R¡A¥hþ¶R? §AÀ´¡A«ç»ò¤£¦»¡ÁÙ¨S¦³®Ö¥i¦r¸¹? XD
¬Ý§Aªºµo¤å¡An¤£n¼gÓµù©ú½²¯»¤Ï¦ê? ¤£µM©È¼uÃĶˤεL¶dªü! XD ·Pı§A¤ñ§ÚÁÙn¶Â½²¸³ªü....XD |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡Gfantasize10140160 |
µoªí®É¶¡:2023/2/17 ¤U¤È 06:04:28
²Ä 1739 ½g¦^À³
|
«O°·¹«~¶·¸g½Ã¥Í¸p³\¥i¡A¤ß®®¹Î¶¤³£¤£¤F¸Ñªk³W¡H¥u¦³§AÀ´¡H¤£¥²¾á¤ß¡C
¸gÀç¥i¥H§ïµ½×¥¿¡A¥i¥H°fÂà³Ó¡C
·sÃÄÁ{§É¹êÅç¶O¥Î°ª©ùÁ|¥@¬ÒµM¡C
¤Ö¼Æ¤j¤áÂ÷¶}µL©Ò¿×¡A¦³½²¸³¦b´N¦n¡A¦pªGÁ{§É¦¨¥\¡A·|¦³¶W¯Å¤j¤á¶i¨Óªº¡A´Nºâ³£¬O´²¤á¤]¨SÃö«Y¡A³o³£¤£«n¡C
¥H¤WºØºØ§AµL»Ý¦h¼{¡A¨¤ß°·±d¡B¥Í¬¡´r§Ö¤ñ¸û«n¡A¡u ¤H¥²¦Û§U¡A¦Ó«á¤H§U ¡v§r¡C
ºÉ§Ö¥h¶R¨Ó¹¥Î§a¡C°O±o¦h¶R¤@¨Ç¡A¦Y¤£§¹¤]¥i¥H¤À¨É¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡Grabbit10136567 |
µoªí®É¶¡:2023/2/17 ¤U¤È 04:52:11
²Ä 1738 ½g¦^À³
|
¥ý§i¶D§Ú½Ã¥Í¸p®Ö¥i¦r¸¹¥i¥H¶Ü? ¤£µM¬O©]¥«Â\»IÃĶÜ? XD
¥xÆW¤§¥ú ¸gÀç¨â¥ú ¥xÆW¤§¥ú ¸êª÷¿N¥ú ¥xÆW¤§¥ú ¤j©@¶]¥ú |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡Gfantasize10140160 |
µoªí®É¶¡:2023/2/17 ¤U¤È 04:10:35
²Ä 1737 ½g¦^À³
|
¡u ½²À´n¦p¦ó¦p¦ó¡K ¡v
¡u ½²¸³À³¸Ó«ç»ò§@¡K ¡v
½²¸³¬O¥xÆW¤§¥ú¡A§A¬O¦ó¤è¯«¸t¡H§A¦³¤°»ò¥ß³õ¨Ó«ü¾É»¡¼L¥xÆW¤§¥ú§r¡H
«Øij§A§â¤ß®®½æ±¼ªº¿ú¡A®³¥h¶R®®¤ß´¼¡B®®¤ß¼Ö¡C §â¤j¸£ÅU¦n¡AÅý¤ß±¡Åܦn¡B¨Ï«äºü²M·¡¡A¤§«á§A·|¨ØªA»P·P®¦½²¸³¡A¦]¦Óµh§ï«e«D¡AÂà¦Ó¦^ÀY¤ä«ù¥xÆW¤§¥ú¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡GOmbudsman10153129 |
µoªí®É¶¡:2023/2/16 ¤U¤È 09:16:36
²Ä 1736 ½g¦^À³
|
¤ß®®«÷¤F10¦~¡AÁÙ¬O¨S¦³¦¨ªG¡A
«ùªÑ3¸U±iªº½²¸³¡A¹ï³o¦¸¼W¸ê®×¡A¤]À³¸Ó®Äªk¡mªk°ê³³ÃÀ®a¤Ú«ß¦è>
±q«eªk°ê¦³¤@¦ì¬ü³N®a¡A¦W¥s¤Ú«ß¦è¡C¥L¬°¤F§ï¨}²¡¾¹¡A ¸ÕÅç¤F¤Q¦~¡A¥Î§¹¤F®a²£¡AÁÙ¬O¨S¦³¤°»ò¦¨ªG¡C
¤Ú«ß¦è¤@ÂI¤]¤£¦Ç¤ß¡C¥L¤S¦b¦Û¤vªº°|¤lùØ¡A«Ø¤F¤@®y½`¡C ¤@¤Á¨Æ±¡³£¥Ñ¦Û¤v¥h°µ¡A¨Ã¥B¤é©]¦u¦b½`ªº®ÇÃä¬Ý¡C³o¼Ë¹L¤F¤T¤Ñ¡A ¥L¨º´²¶ÃªºÀY¾v¡A»êżªºÁy¡A¬Ý°_¨Ó«Ü¹³¤@Ó¤^¤¢¡C
¤S¹L¤F¥|¤Ñ¡A½`¸Ìªº¤õ¤O§ó±j¤F¡A¼ö«×§ó°ª¤F¡A²¡¤]µo¥X¤F¥ú±m¡A ²´¬Ý´Nn¦¨¥\¤F¡A¥i¬O¤ì®ã¿N§¹¤F¡C
¤Ú«ß¦è«æ«æ¦£¦£ªº§âÆX¯¹©Þ¤U¨Ó·í®ã¿N¡CÆX¯¹¿N¥ú¤F¡A¥L®³®à´È¥h¿N¡C ®à´È¿N¥ú¤F¡A¤S®³¤ì§É¥h¿N¡C
¥L¤Ó¤Ó»{¬°¥LºÆ¤F¡A«æ±o¤jú¤j¥s¡C¾F©~Å¥¨ì¤F¡A³£¶]¹L¨Ó¬Ý¡C ¤j®a¥¿Åå©_®É¡A¤Ú«ß¦è«o¸õ°_¨Ó»¡¡G¡u§Úªº¸ÕÅ禨¥\¤F¡I¡v |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡GABC10134671 |
µoªí®É¶¡:2023/2/16 ¤U¤È 12:31:21
²Ä 1735 ½g¦^À³
|
½²ªG¯þ»¡¡A¦Û¤v³ßÅw¥h°¾»·¦a¤è¦æÂå¡A¦]¬°¡uÂ_¤ôÂ_¹qªº¦a¤è¤~¬O¦æÂå³Ì¦³®Äªº¦a¤è¡A¤@¤j°ï»ö¾¹ÃĪ«¤£¨£±o¬O³Ì¦nªºªvÀø¤èªk¡v¡C¥L§óª½¨¥¦Û¤v¡u³Ì°Q¹½ªº¬O·í¥Í§Þ¤½¥qªº¦ÑÁó¡v¡A¦]¬°±`±`n·Ð´o¤½¥q¸Ìªº¦~»´¬ì¾Ç®aÁ~¸ê¨S¦³µÛ¸¨¡C¦ý©M¦~»´ªº¬ì¾Ç®a¤@°_±´¯Á¡B´M¨D¤ß´¼¯e¯fªº¸Ñ¤è¡A¤]¬O¥L³Ì§Ö¼Öªº¨Æ±¡¡C¥L»¡¡G¡u·íµM¡A·sÃĬãµo¦³¶i®i¤F¤]¬O§N·x¦Ûª¾°Ú¡C¡v °Q¹½·í¦ÑÁó´N±M¤ß¬ãµo§a |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡Grabbit10136567 |
µoªí®É¶¡:2023/2/16 ¤W¤È 11:51:13
²Ä 1734 ½g¦^À³
|
·í¯«³QÃÒ©ú¦s¦b µL¯«½×ªÌ¤j¤£¤F¥h±Ð°ó©Î¦ò°ó´N¬O
·í¯«³QÃÒ©ú¤£¦s¦b «H¯«½×ªÌ:....
§ë¸ê²z°]¡A¥È¾Ç¥i°Ñ¦Ò¡A¦ý¤£¤j¦³»ùÈ¡A¤×¨ä¬O«H¥õ½²¸³ªº¡AÁÙ¬O¨Ä¨Ä¥hºÎı§@¹Ú |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G²q·Q10148412 |
µoªí®É¶¡:2023/2/15 ¤U¤È 07:52:21
²Ä 1733 ½g¦^À³
|
¦ò»¡¡A±Ï¤H¤@©R ¡A³Ó³y¤C¯Å¯B±O °²¦p±z¤£«H¦ò¡A´N½Ð®¤§Ú¦h¼L¡I |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡GOmbudsman10153129 |
µoªí®É¶¡:2023/2/15 ¤U¤È 06:40:50
²Ä 1732 ½g¦^À³
|
2021¦~¤ß®®´¿¸g¼W¸ê¤@¸U±i¡A¦ý¬O¦b2021»P2022¦~ªº¦~³ø¤W¡A½²¸³¨Æªøªº«ùªÑ±i¼Æ³£¨S¼W´î¡AÅãµM¥L¬O©ñ±ó¤F2021¦~ªº²{¼W¡C
³o¦¸¤ß®®°]°Èª¬ªp¤w¸g¢¦b¬Ü·û¡A»Ý¿ú¤Õ«æ¡A¤T¤ë©³®£©È´Nn³Ü¦è¥_·¤F¡AªÑ²¼¤w¸g¤UÂd¡At³dÄw´Úªº°]°Èªø¤S³Q¸Ñ¸u¡A§Ú̳o¨Ç´²¤á«H¤ß¤]¸òµÛ´²¥h¡A¤w¸g¦³¡u¶K¾À¯È¡vªº¤ß²z·Ç³Æ¤F¡C
³o¦¸¤ß®®p¹º¶Ò¸ê¤T»õ¤¸¡A¦pªG§Ú¬O½²¸³¡A¬JµM³o»ò¬Ý¦n¤ß®®ªº¥¼¨Ó«e´º¡A¤@©w·|¡u¥ÎºÉ¿ìªk¡v¥hú¨¬ªÑ´Ú¡A²v¥ýÅTÀ³³o¦¸ªº²{ª÷¼W¸ê¡AºÉ¨ì³Ì¤jªÑªFªº°ò¥»¸q°È¡A¥u¦³¥Lµn°ª¤@©I¡A²v¥ýªíºA¡A¤~¯à§l¤Þ²³¦h´²¤áªº¸ò¶i¡C
Á`¤£¯à¤@±ÄÀ©ñ¦n®ø®§¡A¹ªÀy¤j®a¿ãÅDú´Ú¡A³o¦¸¤Sn§â¤j¦n¾÷·|¥Õ¥Õ°eµ¹§O¤H§a¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡GABC10134671 |
µoªí®É¶¡:2023/2/15 ¤U¤È 05:17:56
²Ä 1731 ½g¦^À³
|
¨ºÓ¸s¦³¤H©ñ¸Ü»¡¦bµôû? ³o®ø®§¯u°²? |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤¸´¼9110137200 |
µoªí®É¶¡:2023/2/13 ¤U¤È 04:00:37
²Ä 1730 ½g¦^À³
|
·PÁ²q·Q¤j«ü±Ð ¶¶¨ä¦ÛµM§a¡I·PÁ¡I |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G²q·Q10148412 |
µoªí®É¶¡:2023/2/13 ¤U¤È 02:16:23
²Ä 1729 ½g¦^À³
|
¤¸´¼91¤j ¨Ì·Ó FDA Á{§É³]p«ü«nªººë¯« --- «DDSMB ªº¦¨û¤£À³±µÄ²ª¼©Êªº¸ê®Æ©Î¥i²q´úªºª¼©Ê¸ê®Æ ±z¡§ SND-13 ¤£¥Î¼W¥[¤H¼Æ, ¡K ,¤£¬O¼Æ¾Ú«Ü¦n , ´N¬O«ÜÃa ¡¨ ªº¸ÑŪ , À³¬O«Ü«´¦X³oӺ믫ªº±À½× ¥»¨Ó§Ú¬O±À´ú¤£¼W¼Ë¥»¼ÆÀ³Äݫܦnªº¤@¤è ì¦]¦b©ó 1. ¥_·¥¬PÃÄ·~ªºMPMÁ{§É¤T´Á´Á¤¤¤ÀªR , ¦b110/02/26 µo¥¬«°T ¥_·¥¬PªÍ¶¡¥ÖÀù¤T´Á´Á¤¤¤ÀªR¡A¾ãÅé¥Í¦s´Á¹F³Ì°ªµ¥¯Åªº ²ÎpÅãµÛ®ÄªG¾÷²v80%¥H¤W
(6)µû¦ô«ü¼Ð¡G²Ä¤G¦¸´Á¤¤¤ÀªR®É¶¡ÂI¬°¤w¸gµo¥Í¤F¹w©wªº¥Í¦s´Á¨Æ¥óÁ`¼Æ¡]338¤H¡^ ªº50¢H¡]§Y169¤H¦º¤`¡^¡C®Ú¾Ú¥Ø«e©ÒÆ[¹î¨ì¤§ª¬ªp¡A¦ôºâ¦b¸ÕÅçµ²§ô«áÁ`Åé¥Í ¦s´Á¥iÀò±o²Îp¤WÅãµÛ®ÄªGªº¾÷²v(conditional power: CP)¡CY¬OCP¤j©ó80¢H ¡A«hºû«ù쥻¹w©wªºµû¦ô¨Æ¥ó¡]¦º¤`¡^Á`¼Æ¡AÄ~Äò¦¬®×¡FY¬OCP¤¶©ó50¡ã80¢H¡A «h±N«·spºâ¥Ø¼Ðµû¦ô¨Æ¥ó¡]¦º¤`¡^Á`¼Æ¡FYCP¤p©ó50%¡A¥B¹êÅç²Õ (ADIPemCis) ªº¯f¤H¥Í¦s´Á¸û¹ï·Ó²Õ (PlaceboPemCis) ªº¯f¤Hµu¡A«h²×¤î¸ÕÅç¡C (7)¹ê»Ú¨ü¸ÕªÌ¤H¼Æ¡GÁ{§É¤G/¤T´Á¸ÕÅçºI¦Ü¥Ø«e¤w¦¬¿ý232¤H (8)¨Ì¾Ú°]¹Îªk¤H¤¤µØ¥Á°êÃÒ¨éÂdÂi¶R½æ¤¤¤ß¤§¡u¤W(¿³)Âd¤½¥q«¤j°T®§µo¥¬À³ª`·N ¨Æ¶µ°Ñ¦Ò°Ýµª¶°¡v²Ä¤Q¤@¶µ³W½d:¡u·sÃĬãµo¤½¥qÀ³©óª¾±x·sÃĦU´Á¤HÅéÁ{§É¸Õ Åç(§t´Á¤¤¤ÀªR)µû¦ô«ü¼Ð(endpoint)¤§²Îpµ²ªG®É¡A§Y®Éµo¥¬«¤j°T®§¡v¡C ¤G¡B´Á¤¤¤ÀªR¤§µ²ªG¡G ªÍ¶¡¥ÖÀù¤G/¤T´ÁÁ{§É¸ÕÅç¥Ø«e¤w¦¬¿ý232¦ì¯f±w¡A¦º¤`¤H¼Æ¬°169¤H(§Y¸ÕÅç¹w©w ¥Í¦s´Á¨Æ¥óÁ`¼Æ338¤Hªº50%)¡A®Ú¾Ú¥Ø«e©ÒÆ[¹î¨ì¤§ª¬ªp¡A¦ôºâ¦b¸ÕÅçµ²§ô«áÁ`Åé ¥Í¦s´Á¥iÀò±o²Îp¤WÅãµÛ®ÄªGªº¾÷²v (conditional power: CP) ¤j©ó80%¡A¼fij ·|«Øij¥»¤½¥q«öì¥Ó½Ðpµe«ùÄò¶i¦æ¤T´ÁÁ{§É¸ÕÅç¡C
¥_·¥¬PÃÄ·~Á{§É³]p¨Ã¨S¦³«´¦X FDA ªºÁ{§É³]p«ü«nºë¯« , ©Ò¥H§Ú¤]¦b·Q¤ß®®ªº³]p¬O§_¤]¥i¥H³o¼Ë³]p ? ²¦³º , ¤§«e¤ß®® SND-13 ²Ä¤@¦¸´Á¤¤¤ÀªR¤]´¦¥Ü ¡§ ➢¼W¥[¦¬®×¤H¼Æªº±ø¥ó¡G±ø¥óÀË©w¤O(Conditional Power, CP)¤p©ó80% ¡§ ³o«Ü¹³¥_·¥¬PÃÄ·~ªº³]p --- CP¤j©ó80¢H¡A«hºû«ù쥻¹w©wªºµû¦ô¨Æ¥ó¡]¦º¤`¡^Á`¼Æ ( Ó¤H¸ÑŪ : §Y¤£¼W¼Ë¥»¼Æ )¡AÄ~Äò¦¬®×¡FCP¤¶©ó50¡ã80¢H¡A«h±N«·spºâ¥Ø¼Ðµû¦ô¨Æ¥ó¡]¦º¤`¡^Á`¼Æ ( Ó¤H¸ÑŪ : §Y¼W¥[¼Ë¥»¼Æ )¡FCP¤p©ó50%¡A¥B¹êÅç²Õ (ADIPemCis)ªº¯f¤H¥Í¦s´Á¸û¹ï·Ó²Õ (PlaceboPemCis) ªº¯f¤Hµu¡A«h²×¤î¸ÕÅç¡C ³o´N¬O´Á¤¤¤ÀªRªº¥i²q´ú©Ê ©Ò¥H , ¥_·¥¬PÃÄ·~ªº«°Tª½±µ©ú¥Ü CP ¤j©ó80¢H ¨ì©³¤ß®®«á¨Ó¦³¨S¦³§ó§ïÁ{§Éij©w®Ñ ? YÁÙ¬O²Ä¤@¦¸´Á¤¤¤ÀªRªº´¦¥Ü ¡§ ➢¼W¥[¦¬®×¤H¼Æªº±ø¥ó¡G±ø¥óÀË©w¤O(Conditional Power, CP)¤p©ó80% ¡§ , «h©Î¥i²q´ú CP ¤j©ó 80% ³o¬O¤@ÓÃöÁä
²Ä¤GÓ¬O¦w¥þºÊ´ú©eû·|(Data Safety Monitoring Committee, DSMC)«Øij , ±N²Ä¤@¶¥¬qªvÀø²Õ»P¦w¼¢¾¯²Õ¤§ÀH¾÷¤À°t¤ñ¨Ò¥Ñì³]p¤§1:3½Õ¾ã¬°1:2.5¡C §ÚÓ¤Hªº²q´ú , ³o¦³ÂI·t¥ÜÁ{§É°¾¦V¥¿±ªº¨ý¹D , §_«hYÃĮīܮt , À³ºÉ¦µ²§ô , ¦ó¥²¦h®ö¶O¦¬®×¼Æ©M®É¶¡ ? ³o¤~¬O DSMB ¸Ó°µªº !
²Ä¤TÓ 2aªº¼Æ¾Ú¹ê¦b¤Ó¦n , °£«DÀø®Ä¦³ªF¡B¦è¤è¤HºØªº®t²§
´N¬O¦]¬° Abilify ¦b¬YÓÁ{§Éªº³]p Favorable Zone : CP ¡Ù 80% ¤£¥[¼Ë¥» Promising Zone : 80% > CP ¡Ù 30% ¼W¥[¼Ë¥» Unfavorable Zone : 30% > CP ¡Ù 15 % ¤£¥[¼Ë¥» ¥BÁÙ¦³³]p ¡§ ¶W®Ä ¡§ ©Î ¡§ µL®Ä ¡§ ªº±ø¥ó , ¦Ó´£«eµ²®×ªº³]p
©Ò¥H , §Ú²{¦b©ê«ùµÛ¼ÖÆ[¤¤ªº¤¤©Ê¬Ýªk --- Áö¼ÖÆ[ , ¦ýÁÙ¬O¤ß¦sFDA Á{§É³]p«ü«nªººë¯«
¥H¤W¬Ýªk , ¶È¬°§ÚÓ¤Hªº°¾¨£ ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a !
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤¸´¼9110137200 |
µoªí®É¶¡:2023/2/13 ¤U¤È 12:27:39
²Ä 1728 ½g¦^À³
|
½Ð°Ý²q·Q¤j SND-13 ¤£¥Î¼W¥[¤H¼Æ,¯u¥¿ªº·N¸q¬O¤°»ò,¤£¬O¼Æ¾Ú«Ü¦n´N¬O«ÜÃa¬O³oÓ·N«ä¶Ü¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡GOmbudsman10153129 |
µoªí®É¶¡:2023/2/13 ¤U¤È 12:09:46
²Ä 1727 ½g¦^À³
|
ÁÂÁ§Aªº´£¿ô¡C
¦~¬ö¤j¤F¡A¦ü¥G¤w¦³»´«×¥¢´¼¯gªº¼xÔ¤F¡A¦ý¬OÂå®v»¡¡A¹ï³oÓ²{¶H¡uµLªk¦h°µ¸àÄÀ¡v¡C
¦b111/8/24ªº«°T¡G¡u¦w¥þºÊ´ú©eû·|«Øij¡AÄ~Äò¶i¦æÁ{§É¸ÕÅç¡A¤£°µ¥ô¦ó½Õ¾ã¤H¼Æ¡C¥»¦¸¤ÀªR¨ÃµL¸Ñª¼¡A¥BµL²Îpµ²ªG¡A¬G¥»¤½¥q¹ï©óDSMC«ØijµLªk¦h§@¸àÄÀ¡v
¤½¥q¹ï³oÓ¡u«°T¡v»´´y²H¼g¡A¬Æ¦ÜÁÙ±j½Õ¡uµLªk¦h§@¸àÄÀ¡v¡A¨º»òªÑªF§ó¬O¬ÝªºÃú·Ù·Ù¡A¦p¦ó¹ï¤½¥q¥¼¨Ó¦³§ó¦h«H¤ß¡H
¤ÏÆ[¡A¦b111/7/31©xºôµo¥¬·s«a¤G´ÁÁ{§Éµ²ªG¡A©ú©ú¨S¦³¹F¨ì¡u¯f¬r¶qÅãµÛ´î¤Ö¡vªº¡u¥Dn«ü¼Ð¡v¡A¦ý·s»Dªº¥DÃDÁÙ¯S§O±j½Õ¡G¡u¤ß®®¥ÍÂ夽¥¬COVID-19¤fªA§Ü¯f¬rÔ¿ï·sÃÄPentarlandir® ¥¿±¤§¤G´ÁÁ{§Éµ²ªG¡v
¬Ý§¹³o¤GÓ¤½§iªº¤º®e¡A·|¥O§Úºë¯«¿ù¶Ã¡A¬Ý¨Ó§Ún¥h°Ñ¥[SND13ªºÁ{§É¸ÕÅç¤F¡C
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G²q·Q10148412 |
µoªí®É¶¡:2023/2/13 ¤W¤È 06:21:31
²Ä 1726 ½g¦^À³
|
Ombudsman ¤j
½Ð°Ñ¦Ò 111/08/24 «°T ¥»¤½¥q¦¨¤Hºë¯«¤Àµõ¯g¥[¦¨ªvÀøNaBen(SND13)¤G(b)/¤T´Á¤HÅéÁ{§É¸ÕÅç±µÀò¦w¥þºÊ´ú©eû·|(DSMC)¤§«Øij
(2)¦w¥þºÊ´ú©eû·|«Øij¡G¦w¥þºÊ´ú©eû·|«Øij¡AÄ~Äò¶i¦æÁ{§É¸ÕÅç¡A¤£°µ¥ô¦ó½Õ¾ã¤H¼Æ¡C
§Ú«Ü¯Ç´e , ¬°¤°»ò¤j®a¦h¦Õ¼ô¯à¸ÔªºªF¦è , ±z¦h¤£ª¾¹D ?
¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a !
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡GOmbudsman10153129 |
µoªí®É¶¡:2023/2/12 ¤U¤È 10:27:23
²Ä 1725 ½g¦^À³
|
²q·Q¤j
§A»¡SND13¡G¡u²{¦b¸g´Á¤¤¤ÀªR¤w¤£¥²¼W¥[¼Ë¥»¼Æ¡v¡AÀ³¸Ó¬O§A²q·Qªº§a¡H
§Ú¬d¹L¤ß®®©xºô¡A¦b2020¦~7¤ë26¤é¤½¥¬ªº¡uSND13´Á¤¤¤ÀªR¡v¤¤¡A¦³´XÓ«n¤º®e¡G
¤@¡BDSMC«Øij: ¬°·V«°_¨£¡A±N©ó¥t¤T¤Q¤H§¹¦¨¸ÕÅ礧«á¦A¶i¦æ½Õ¾ã¤H¼Æ¤ÀªR¡C¡]¬°¦ó¸ò¤@¶}©lªº»¡ªk¤£¦P¡Aµo¥Í¤F¤°»ò¨Æ¡H¡^
¤G¡B¥»´Á¤¤¤ÀªR¨Ã«D¸Ñª¼¡A§Ṳ́£ª¾±xPANSSÁ`¤À¡B pÈ¡B®ÄªG¶q(effect size)µ¥¦U¶µ¼Æ¾Ú¡C¡]´Á¤¤¤ÀªR¨Ã«D¸Ñª¼¡A¤@¥y¸Ü»´´y²H¼g¡A¦p¦ó¼W¥[§ë¸ê¤H¹ï³oÓ¸ÕÅ窺«H¤ß¡H¡^
±q¦¹¥H«á¡A¦³ÃöSND13ªº®ø®§«K¦b©xºô¤W®ø¥¢¤F¡AÅý§Ú¹ïSND13ªº«H¤ß·U¨Ó·U§C¡A¤G¦~¦h¨Ó§Ú¤@ª½«Ü¯Ç´e¡G¥t¥~¤T¤Q¤H¬O§_¤w¸g§¹¦¨¸ÕÅç¡HDSMC¬O§_«Øij¼W¥[¦¬®×¯f¤H¼Æ¡H
¦pªG¡u²q·Q¡v¤j»¡ªº«H®§¬O¡u¥¿½T¡vªº¡A¬°¦ó¤½¥q¿ð¿ð¤£¤½¥¬¡H ³oºØ«H®§ªº¤£³z©ú¡A¤£¶È¥´À»¤F§ë¸êªÌªº«H¤ß¡A¤]¤Ï¬M¤F°õ¦æªøªººÞ²z¯à¤O¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡GABC10134671 |
µoªí®É¶¡:2023/2/12 ¤U¤È 09:31:26
²Ä 1724 ½g¦^À³
|
¥þºÖ¥Í§Þ¦]¦w´I°òª÷¤JªÑ¦¨²Ä¤@¤jªÑªF«á¡A¸³¨Æ·|8¤é§ï²Õ¡A·s¥ô¸³¨ÆªøªL¸sªí¥Ü¡A¤µ¦~±N¥H¼W¥[¸gÀç¹Î¶¤¦¨û¡B¦~¤¤¦A±Ò°Ê¼W¸ê¤Î±À¶i°®²´¯g·sÃÄBRM421ªº¤T´ÁÁ{§É¸ÕÅç©M°ê»Ú±ÂÅv¬°¥Ø¼Ð¡A³Ì§Ö2025¦~°e¥ó¥Ó½Ð¬ü°êÃÄÃÒ¡A·m§ð¥þ²y¶W¹L30»õ¬ü¤¸°Ó¾÷¡C
2013¦~¥Ñ²®ü¬À³Ð¥ßªº¥þºÖ¥Í§Þ¡A³Ì¤j«ùªÑ¬°ªL¸s³Ð¥ßªº¦w´I°òª÷¡B«ùªÑ¤ñ12.9¢H¡A¥t¯q¹©¶°¹Î«ùªÑ3.84¢H¡BÑÔ¼w¶°¹Î3.71¢H¡B¤¤¥[¶°¹Î3.61¢H¡C
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G²q·Q10148412 |
µoªí®É¶¡:2023/2/12 ¤U¤È 07:33:37
²Ä 1723 ½g¦^À³
|
Ombudsman ¤j
2013 ¥Zµn¦b JAMA ªºÁ{§É³ø§i , ½Ð°Ñ¦Ò Add-on Treatment of Benzoate for Schizophrenia A Randomized, Double-blind, Placebo-Controlled Trial of d-Amino Acid Oxidase Inhibitor
jamanetwork.com/journals/jamapsychiatry/fullarticle/1746121
¤ß®®´N¬O¥Î³oÓÁ{§Éµ²ªG , ¦ÓÀò±o FDA ªº BTD 2015 ÁÙÀò±o¬ü°êµÛ¦W´¼®w¤§¤@ªº¥¬¾|ª÷´µ¬ã¨s©Ò ( The Brookings Institution ) ¿ï¬°¬ã°Q·|¥DÃD¤§¤@ ( Case Study 7: NaBen ) Breakthrough Therapy Designation: Exploring the Qualifying Criteria April 24, 2015
www.brookings.edu/wp-content/uploads/2015/03/Breakthrough-Therapy-Designation_final.pdf
¨ä¦¸ °²¦p DSMB ¦b´Á¤¤¤ÀªR«Øij¼W¥[¼Ë¥»¼Æ , ¨º¯uªº´Nªí¥Ü³o¶µÁ{§É³]p¬O¥¿½Tªº §_«hµ¥¨ì348¤H©Ûº¡¸Ñª¼ , ¤~¦]¼Ë¥»¤£¨¬¦Ó¥¼¹F¼Ð , ¨º¹L¥hªáªº¿ú©M®É¶¡³£·|ºÉ¥IªF¬y , Y·Q¦A°µ3´Á , ¥²¶·«°_Äl¨_ ¦ý¥H²{¤µªº³]p , 2b©Ò©Ûªº±wªÌÁÙ¬O¥i¥H¨Ö¤J3´Á²Îp , ¤£·|§Î¦¨¸êª÷©M®É¶¡ªº®ö¶O Y¦]¦¹¦Ó³y¦¨¥«³õªº¾_¾Ù , ©Î¤]¬O¥²n¤§´c ¦]¬°²{¦b¸g´Á¤¤¤ÀªR¤w¤£¥²¼W¥[¼Ë¥»¼Æ , ©Î¤~·|³y¦¨¤j®a¹ï²{¤µ³]pªº»~¸Ñ
¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a !
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡GOmbudsman10153129 |
µoªí®É¶¡:2023/2/12 ¤U¤È 05:44:20
²Ä 1722 ½g¦^À³
|
²q·Q¤j¡G
1. ¦pªGSND13¦³§¹¦¨¤G´ÁÁ{§É¸ÕÅç¡A¬°¦ó§Ú̳£¨S¦³¦b¤ß®®©xºô»Pclinicaltrials.gov³£¨S¦³¬Ý¨ì³oÓ¸ÕÅ窺¤º®e»Pµ²ªG¡H
2. ÁöµM2b/3ªº¸ÕÅç³]p¥i¥H¼W¥[¼u©Ê¡AÁקK¼Ë¥»¼Æ¤Ó¤p¡A¼vÅT²Îp¤ÀªRµ²ªG¡A¦ý¬O¦pªGìqn©Û¶Ò348¤H°Ñ»P¸ÕÅç¡A°µ¨ì¤@¥b®É¡A«o¬ðµM§i¶D¤j²³¡GFDA±M®a«Øijn¼W¥[¨ì600¤H¥H¤W¡A¸Õ°Ý¡G³oÓ®ø®§·|¤£·|Åý§ë¸ê¤H¥H¬°¡uÃĮĤ£¨Î¡v¡A¦ÓÀ~¥X¤@¨§N¦½¡H³o¹ï§ë¸ê¤Hªº«H¤ß¡]¤£ºÞ¬O¾÷ºc§ë¸ê¤H©Î´²¤á¡^³£¬O«Ü¤jªº½ÄÀ»¡C
3.¦pªG¤½¥qªº¸êª÷³W¹º¤]³£¬O®Ú¾Ú¡u³Ì¼ÖÆ[¡vªºµ²ªG¡A¤@¥¹¥²¶·¼W¥[¼Ë¥»¼Æ®É¡A¤½¥qªº¸êª÷¬O§_¨¬°÷À³ÅÜ(adaptive)¡H |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡GABC10134671 |
µoªí®É¶¡:2023/2/12 ¤U¤È 04:19:04
²Ä 1721 ½g¦^À³
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G²q·Q10148412 |
µoªí®É¶¡:2023/2/12 ¤U¤È 02:10:34
²Ä 1720 ½g¦^À³
|
Ombudsman ¤j ¤ß®®Y¨S¦³¤G´Á¸ÕÅç , þ¨ÓªºÁ{§Éµ²ªGÀò±o BTD 2b+3 ¬O¥[¤F¤@¹D«OÀI , ¥i¥H¬Ý¬Ý 2b ªºÀø®Ä±¡ªp , µø±¡ªp×¥¿¼Ë¥»¶q , §ó¥[½T«OÁ{§Éªº¼u©Ê Y¨S¦³³oÓ¼u©Ê , ¸U¤@ì¥ý³]pªº¼Ë¥»¶q¤£¨¬ , ¦Ó³y¦¨¸Ñª¼¥X²{¦]¼Ë¥»¤£°÷ªº¥¢±Ñ , ³o¼Ë´N·|³y¦¨±ý³t«h¤£¹Fªº±¡ªp ¯Âºé´N¨Æ½×¨Æ , µL¥L·N
¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a !
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡GOmbudsman10153129 |
µoªí®É¶¡:2023/2/12 ¤U¤È 12:37:22
²Ä 1719 ½g¦^À³
|
2b/3Á{§É¸ÕÅç¬O¤ß®®³Ì¨Îªºµ¦²¤¶Ü¡H
¹L¥h¥H¨Ó¡A¤ß®®¤@ª½¸ØÄ£¨ú±o¤F¡u©t¨àÃÄ¡v¡B¡u¬ð¯}©ÊÀøªk¡vªº¸ê®æ¡A¨Ã¥B¨ú±o¤F¥|Ó FDA®Ö㪺2b/3Á{§É¸ÕÅç¸ê®æ¡A¬Ý¦ü¥i¥HÁYµu·sÃĶ}µoªº®É¶¡¡A³Ì«á«o¡u±ý³t¦Ó¤£¹F¡v¡AÁÙ³´¤J¸êª÷§Y±N§iÁjªº§x¹Ò¡C
¨s¨äì¦]¡A¨ä¤@¬O¨«¿ù¸ô¥h¶}µo·s«a·sÃÄ¡A¨ä¤G¬O±Ä¨ú¤¤¼Ï¯«¸gÃĪ«2b/3ªºÁ{§É¸ÕÅ給²¤¡C
¶i¦æ2b/3Á{§É¸ÕÅ窺¦n³B¡A¬O¤£»Ýn¶i¦æ¤G´ÁÁ{§Éµ²ªGªº¸Ñª¼¡A¦Ó¬Oµ¥¨ì§¹¦¨¤T´ÁÁ{§É¸ÕÅç¤~¸Ñª¼¡A³o¼Ë°µ¬Ý¦üÁYµu¤F¬ãµo®É¶¡¡AµM¦Ó¹ï¤ß®®³oºØ¯Ê¥F¸êª÷ªº¤p¤½¥q¤£¤@©w¬O³Ì¨Îªºµ¦²¤¡C
¦ôp°µ§¹¤@Ó¤¤¼Ï¯«¸gÃĪ«ªº2b/3Á{§É¸ÕÅç¡A©Ò»Ý¸g¶O°ª¹F3»õ¤¸¥H¤W¡A³oÁÙ¤£«OÃҸѪ¼·|¦¨¥\¡A¥Ñ©ó¨S¦³¤½¥¬¤G´ÁÁ{§Éªºµ²ªG¡A´NµLªk§Q¥Î¤G´ÁÁ{§É¸ÕÅ窺¦¨¥\¬G¨Æ¨Ó§l¤Þ§ó¦h¾÷ºc§ë¸êªÌªºª`¸ê¡A¦Ó¥²¶·¦~¦~¦V즳ªºªÑªF¦ù¤â¡A¨Ï±o°]°Èªø¨C¦~³£n¬°Äw¿ú¶Ë³z¸£µ¬¡C
µM¦Ó¡AªÑªFªº@¤ß¡B«H¤ß»P¤f³U²`«×³£¬O¦³«×ªº¡A¦pªG¥Ø«e¥¿¦b¶i¦æSND13ªº2b/3Á{§É¸ÕÅç¡A¥²¶·µ¥¨ì2025¦~¤~¯à¸Ñª¼¡A¥¼¨Ó³o¤G¦~µ°T¥þµL¡A¸Õ°Ý¡AÁÙ¦³¦h¤ÖªÑªFÄ@·NÄ~Äò±Ç¿ú»{ªÑ¡A°µ¤ß®®ªº¤j¹Ú©O¡H |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡GOmbudsman10153129 |
µoªí®É¶¡:2023/2/12 ¤U¤È 12:07:56
²Ä 1718 ½g¦^À³
|
ÉÃèAxsomeªº¦¨¥\¸gÅç
1. Axsomeªº°õ¦æªø¤]¨ã¦³Âå¾Ç¡B¤À¤l¥Íª«¾ÇªºI´º¡A¦ý¥Lªø´Á¦bµØº¸µóªº§ë¸ê»È¦æ¾á¥ô²£·~¤ÀªR®v¡A³oÓ¸gÅ禳§U©ó³o®a·s³Ð¥ÍÂ夽¥qÀÀ©w§ó¥¿½Tªº¶Ò¶°¸êª÷µ¦²¤¡C
2.°õ¦æªø¥²¶·±M¤ß©ó¥»·~¡A¤£¯à¹³¤ß®®ªº°õ¦æªø¡A¥i¥H¤@¤ß¥|¥Î¡A¤£¶È¨É¨ü°õ¦æªøªº«Ý¹J¡AÁÙn¨É¦³µo©ú®a°|¤hªººaÅA¡A¦P®ÉÁÙn¦b¬ü°êª¾¦W¤j¾Ç§@¨|^¤~¡A¨Ã¥BÁÙ¯à¦æ¦³¾l¤O¦bÂå¾Ç¤¤¤ßÄa³ýÀÙ¥@¡C
3. Á{§É¸ÕÅ礣¨«±¶®|¡GAxsome¤½¥q¥H¤EÓ¤ë®É¶¡«K¨ú±o¡u¤G´ÁÁ{§É¸ÕÅç¡v¦¨¥\«á¡A¦ôp©Ò»Ý¸g¶O¶È»Ý¥x¹ô5¤d¸U¦Ü1»õ¤¸¡A³o¤j¤j´£°ª¤F±M·~¾÷ºc§ë¸êªÌªº«H¤ß¡A¿ãÅD°Ñ»P¸Ó¤½¥qªº¼W¸êpµe¡AÅý¤½¥q¤@Á|¶Ò±o¬ù7»õ¤¸¸êª÷¡A½T«O¤T´ÁÁ{§É¸ÕÅçµL«áÅU¤§¼~¡A±q¦Ó¯à¦b¤@¦~¤º¨³³t§¹¦¨¤T´ÁÁ{§É¸ÕÅç¡A¨Ã¨ú±o¦¨ªG¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡GABC10134671 |
µoªí®É¶¡:2023/2/12 ¤W¤È 11:45:10
²Ä 1717 ½g¦^À³
|
¨Ó¨ì¶QÄ_¦a±ÀÂˤ@ÁûÃĤ£¤G»ù200¤¸ ¸g¹L¤@¬q®É¶¡¥un10¤¸
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡GOmbudsman10153129 |
µoªí®É¶¡:2023/2/11 ¤U¤È 12:43:32
²Ä 1716 ½g¦^À³
|
2022¦~8¤ë19¤éÁ`¤½¥q¦ì©ó¬ü°ê¯Ã¬ù¥«ªºAxsome Therapeutics ¤½¥q«Å§G¡A¸Ó¤½¥q¶}µoªº¡u««×¼~Æ{¯g¡vªº·sÃÄÀò±o¬ü°êFDAªº¤W¥«³\¥i¡C
³o®a¦¨¥ß©ó2012¦~1¤ëªº·sÃĶ}µo¤½¥q¡A¥u¤ñ¤ß®®¥ÍÂ妤@¦~¦¨¥ß¡A¨äÃĪ«ªº§@¥Î¾÷ÂàNMDA¡A¤]¬O»P¤ß®®¬Û¦P¡AµM¦Ó¸Ó¤½¥q«o¯à¦b¤Q¦~¤º¡AÀò±o²Ä¤@ӳзsªºÃÄÃÒ¡A¸Ó¤½¥q°õ¦æªøªº°õ¦æ¯à¤O½T¹ê¥O¤H¨í¥Ø¬Û¬Ý¡C
±q¸Ó¤½¥qºô¯¸µo¥¬ªº·s»D¥iª¾¡A¸Ó¤½¥q¶È¶È¥Î¤F20Ó¤ë¡A«K¥ý«á§¹¦¨¤G´Á»P¤T´ÁÁ{§É¸ÕÅç¡A¤ÏÆ[¤ß®®¦b¤¤¼Ï¯«¸gÃĪ«Á{§É¸ÕÅ窺¤û¨B¤Æ¡A´N³s°_¨B³Ì¦ªº¡u«C¤Ö¦~ºë¯«¤Àµõ¯g¡vªºÁ{§É¸ÕÅç§ó¬O¤£¤F¤F¤§¡A¤G®a¤½¥q°õ¦æªøªº°õ¦æ¯à¤O°ª¤U¥ß§P¡G
¥H¤U¬O¸Ó¤½¥q¶}µo³o¶µÃĪ«ªº¥Dn¨½µ{¸O
2018,05 ¶}©l¶i¦æ¡u««×¼~Æ{¯g¡vªº¡u¤G´Á¡vÁ{§É¸ÕÅç ¡]©Û¶Ò97¤H°Ñ»P¸ÕÅç¡AªAÃÄ6¶g¡^
2019,01 «Å§G¤G´ÁÁ{§É¸Ñª¼¦¨¥\ ¡]¤G´ÁÁ{§É¸ÕÅç¥uªá¤F9Ó¤ë¡^
2019,01 «Å¥¬µo¦æ288¸UªÑ¡A¨CªÑ8¬ü¤¸¡C¦@¶Ò±o2330¸U¬ü¤¸¡C
2019,06 ¶}©l¶i¦æ¡u««×¼~Æ{¯g¡vªº¡u¤T´Á¡vÁ{§É¸ÕÅç ¡]©Û¶Ò327¤H°Ñ»P¸ÕÅç¡AªAÃÄ6¶g¡^
2019,12 ««×¼~Æ{¯gªº¤T´ÁÁ{§É¸ÕÅç¸Ñª¼¦¨¥\ ¡]¤T´ÁÁ{§É¸ÕÅç¥uªá¤F7Ó¤ë¡^
2019,12 ªÑ²¼¥¿¦¡¤W¥«¡Aµo¦æ230¸UªÑ¡A¨CªÑ87¬ü¤¸¡A¦@¶Ò±o2»õ¬ü¤¸
2022,08 ««×¼~Æ{¯g·sÃÄÀò±o¬ü°êFDA®Öã¤W¥«
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡GABC10134671 |
µoªí®É¶¡:2023/2/11 ¤W¤È 10:45:01
²Ä 1715 ½g¦^À³
|
10¤¸«K©y¶Ü ¬O¶Àª÷500³£¤£¶Q
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡GOmbudsman10153129 |
µoªí®É¶¡:2023/2/10 ¤U¤È 08:28:54
²Ä 1714 ½g¦^À³
|
¨¬°¤@®a¾Ö¦³¤»¤d¦h¦ìªÑªFªº¤ß®®¥ÍÂ媺Á`¸g²z¡A¬O§_¥i¥H¡u¤ºÁ|¤£Á׿ˡv¡H
®Ú¾Ú¤ß®®111¦~ªº¦~³ø¡A111¦~4¤ë1¤é¸u¥ô§d¶®¬Â¬°µ¦²¤ªø¡A¤]¾á¥ô¤ß®®¬ü°ê¤l¤½¥qSyneuRx Lifesicenceªº°õ¦æªø¡A¦P®É®Ú¾Ú¦~³ø´¦ÅSªº°T®§¡A§d¤k¤h¥¿¬O½²ªG¯þÁ`¸g²zªº°t°¸¡C
ÁöµM§d¤k¤h¬O¬ü°ê³Ç¥Xªº¸gÀپǪ̡A¦ý¬OÁ`¸g²z½²ªG¯þ¸u¥ô¦Û¤v¤Ó¤Ó¾á¥ô¤½¥qªº°ª¯Å¥DºÞ¡A¹ê¦b¨Ã¤£«ê·í¡A¤×¨ä¬O¤½¥q¥Ø«e¦b¸êª÷¯Ê¥F¤U¡A¬°¤F¾ê¸`¶}¤ä¡A¤G¦ì°ª¯Å¥DºÞ³£¦P®É¥h¾¤F¡A§Ú¤£¸Ñ¦ó¥H¿W¿W¯d¤U§d¤k¤h¡H
¨ä¹ê¡A§Ú´¿´N¡u¤ºÁ|¤£Á׿ˡvªº°ÝÃD¼x¸ß¹L´X¦ì¾á¥ô¤W¥«¤½¥q°ª¯Å¥DºÞ¡A¥L̳£²§¤f¦PÁnªº¦^µª¡A¤½¥q³£¦³©ú¤å³W©w¡G¡u¤Tµ¥¿ËÄݤ£±o¥ô¾©ó¦P¤@¤½¥q¡A¤£½×³o¨Ç¿ËÄݪº¯à¤O¦³¦h±j¡v¡C¥Dn¬O¬°¤FÁקK¤j²³«ùªÑªº¤½¥qÅܦ¨¤F®a±Ú¥ø·~¡A¥H¤Î¦]¤§¥i¯àl¥Íªº¤º³¡ºÞ²z°ÝÃD¡C
§Ú·Q½Ð°Ý¤ß®®ºÞ²z¶¥¼h¡A¨¬°¤@®a¾Ö¦³¤»¤d¦h¦ìªÑªFªº¤ß®®¥ÍÂ媺Á`¸g²z¡A¬O§_Ä@·N¡u¤j¸q·À¿Ë¶Ü¡v¡H |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡GABC10134671 |
µoªí®É¶¡:2023/2/10 ¤U¤È 08:23:35
²Ä 1713 ½g¦^À³
|
¦Y´¶®³¯k¤]¥i¥H§ïµ½¯gª¬ÁÙ¹FÅãµÛ®t²§ ¨S¹FÃä¼Ð´N¬O¨S¹F¼Ð |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G²q·Q10148412 |
µoªí®É¶¡:2023/2/10 ¤U¤È 06:59:57
²Ä 1712 ½g¦^À³
|
½Ð¤£n¥H¦¨±Ñ½×^¶¯ Ó¤Hı±o¥H·í®É¬Ì±¡ªº±¡ªp , ¤ß®®°µ¤G´Áªº¨Mµ¦¬O¥O¤H¹Å³\ªº °²¦p¤G´Á¼Æ¾Ú¬O¤ñ¥Ø«eªº°T¸¹©úÅã¥BÀu¨q , ¬Û«H¤£¬O¤µ¤Ñªº®ð¶H , ¬Ý¬Ý½÷·çªºÃĽæ¤F¦h¤Ö´Nª¾¹D¤F ¥»¨ÓÁ{§Éµ²ªG´N¦³Àu¦H , ¤£¹Á¸Õ«ç»ò·|ª¾¹D¦n¤£¦n , ªp¥B¬Y¨Ç¯S©w¶µ¥ØÁÙ¹FÅãµÛ®t²§ , ¥H60¤Hªº¼Ë¥»¶q¬O¤£®e©öªº ·íµM , ¬°¤µ¤§p , Y¦³ª÷¥DÄ@·N¤ä«ù¹Á¸Õ , ¤]¬O¬°¤HÃþ°µ¤F¤@¼Î¦n¨Æ ½Ð¤j®a©¹«e¬Ý§a ¤@®Éªº¤£¦p·N , ¤£¥Nªí¥H«á¨S«e´º ¤]½Ð¸gÀ綥¼h°O¨ú±Ð°V , ¥¼«Bº÷Á[ , ³W¹º¦n²{ª÷¬y¶q , ¥H³Æ¤£®É¤§»Ý
¥H¤W¶È¬OÓ¤H·N¨£ , Y¦³¥t¥~¬Ýªkªº¤j¤j , ½Ð®ü²[ ! ¦ý§Ú¹ï¦¹Ä³ÃD±N¤£¦A¦^À³ ÁÂÁ¤j®a !
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡GOmbudsman10153129 |
µoªí®É¶¡:2023/2/10 ¤U¤È 05:58:33
²Ä 1711 ½g¦^À³
|
½¶}¤ß®®¥ÍÂå111¦~ªº¦~³øªºº¶¡A¤æ¤jªº¦r´¦òU¤F¤ß®®¥ÍÂ媺Ä@´º¡G
¡uPatients & Families First ¡G¥H¯f±wªº»Ý¨D¬°ºn¦Ò¶q¡A³Ð³y¤@¨t¦C·s¿oªº²£«~¡A¥i¥H¼sªxªº¨Ï¥Î¦b¦UºØ¡u¤¤¼Ï¯«¸g¡v¯e±w¡A¤£ºÞ¬O«Ä¨à̩άO¦~ªøªÌ³£¥i¥H¦w¥þ¦³®Äªº¨Ï¥Î¡C§Æ±æ§Ṳ́@°_§V¤O¡A«¬B¤ßÆFªº³ß®®¡C¡v
¦b³o¬q¤å¦r¤¤¯S§O±j½Õ¡G¡u¤ß®®±N³Ð³y¤@¨t¦C¥i¼sªx¥Î©ó¤¤¼Ï¯«¸gªº¯e¯f¡v¡A¦ý¬O³o¤T¦~¨Ó¡A¤ß®®ÅãµM¨«¿ù¤F¤è¦V¡A±N¦n¤£®e©ö¥Ñ²³¦hªÑªF¶Ò¨ìªº¸êª÷§ë¤J¨ì¡u·s«a¡vÃĪ«ªº¬ãµo¡A¤G´ÁÁ{§É«o¥H¥¢±Ñ§i²×¡A¤~³y¦¨¤½¥q¥Ø«e¸êª÷ªº¹¼¥F¡A¨Ã¥BÅý¤£¤ÖªÑªFÌ¥¢±æ¡C
ÀHµÛ¬Ì±¡ªºÁͽw¡A¤ß®®¤£¦ý¤£Äa±V°Ç°¨¡A«·s¦^¨ì¥¿y¡A¤Ï¦Ó¦b¼Æ¤ë«eªºªk»¡·|¤W¡AÁ٥祤jªº½g´T½Í·s«aªº«áÄò¬ãµo¡A¬Æ¦Ün¶}µo»ó¼Q¾¯«¬¡C
§Ú·Q°Ý¡A¤ß®®ªº¥DºÞ¶¥¼h¦ó®É¤~·|¿ô®©¡H |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G§õÁ`²Î10135593 |
µoªí®É¶¡:2023/2/7 ¤U¤È 03:32:23
²Ä 1710 ½g¦^À³
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G²q·Q10148412 |
µoªí®É¶¡:2023/2/6 ¤U¤È 07:05:19
²Ä 1709 ½g¦^À³
|
«Îº|§ó¾D³s©]«B¡A²î¿ð¤S¹J¥´ÀY·
Às´å²L¤ô¾D½¼À¸¡Aªê¸¨¥¶§³Q¤ü´Û
®Ú²`¤£©È··n°Ê¡A¾ð¥¿µL·T¤ë¼v±×
¦ý¦³ºñ·¨³ôô°¨¡A³B³B¦³¸ô³qªø¦w
¤j®a©Î®¼¦í ¤ß®®½Ð¥[ªo
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡GPeter Lin10152815 |
µoªí®É¶¡:2023/2/5 ¤U¤È 02:26:01
²Ä 1708 ½g¦^À³
|
to:Cliff ²{¼W¥h»{¡A¤½¥q´N¦³¿ú§@§¹¤T´Á¡C
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡GCliff10135274 |
µoªí®É¶¡:2023/2/4 ¤U¤È 10:32:07
²Ä 1707 ½g¦^À³
|
°ÆÁ`¡B°]°Èªø¬ÛÄ~Â÷¾¡Aºë²¤H¨Æ¡A¼Á¸`¶}¤ä¡FÁö¤µ¤é¥ß¬K¡A¤½¥q«o¤~n·Ç³Æ§t¤ô¶V¥V¡C ·|¤£·|´N¦¹¶i¤J¥ð¯vª¬ºA¡A¬Æ¦Ü¤£¿ô¡H¦ó®É¯à¦AÄ~Äò¦¬®×¡H
¥b¯a¤è¶í¤@Ų¶}¡A¤Ñ¥ú¶³¼v¤£±r«Þ¡A°Ý´ë¦ó¤é²M¦p³\¡A´n¼Û¬¡¤ô¤£¦A¨Ó¡C ²rªê°Z¦b·í¹Dª×¡A§xÀs¥ç¦³¤É¤Ñ®É¡C
½Ð°ª¼h·P©ÀªÑªF»a¥ÍÌÀE»Ë·L¶q¦p²\®÷¡A®þ®þ¯×»I¦å¦½ºw¡A²öÅýªÑ²¼½k¦¨¾À¡A¥É¥ÛѵI¹LÃø©è¡C ¯dµ¹ªÑªF̤@±ø¥Í¸ô§a¡I
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤p·10148067 |
µoªí®É¶¡:2023/1/4 ¤U¤È 03:36:46
²Ä 1706 ½g¦^À³
|
½²±Ð±Â¦b¤ß®®Ãø¹D¥u¬O¦bÝ®t¶Ü¡H |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¾å¦à10141996 |
µoªí®É¶¡:2023/1/4 ¤U¤È 12:02:03
²Ä 1705 ½g¦^À³
|
Cliff¤j »P ²q·Q¤j ³£¬O¨}µ½ªº¤H¡A¤@ª½¨S§@¤Ó¹L¦y¾Uªº§åµû¡C
´I¨¹Ãã¥h¥D¿ìú³°Ó¡AÓ¤Hªº¸ÑŪ¬O¡G ¤w¸gµ¹¤F«Üªø¤[ªº®É¶¡¡A³o¬q®É¶¡ªº±µÄ²»PÆ[¹î¡Aµoı¤ß®®ªº CEO ½²±Ð±Â¤£¦ýÁ{§ÉÀt³t¡A¥BÃø¥H«H¥ô¡A ¬°¤F´I¨¹¦Û¤vªºÁnÅA¡A¤£Ä@¦AÄ~Äò¦X§@¤U¥h¡C
Ó¤Hªº¬Ýªk¬O¡G ½²±Ð±Â¥²¶·¦b¸gÀ礽¥q»P±Ð¾Ç¤§¤¤¡A¤GªÌ¾Ü¨ä¤@¡A¥u¯à±Mª`©ó¨ä¤¤ªº¤@¶µ¡C ¦ý¨ì¤µ¤ÑÁÙ¨S¬Ý¨ì¦³¤Hª½±µÀË°Q³oºØ CEO ¤£±Mª`©ó¤½¥q·~°È±À°Êªºµo¤å¡C ¦pªG¨âÃäÁ~¸êĸS³£¦³®³¡AÓ¤Hı±o§ó¬O¹ï¤£°_¤ß®®ªºªÑªF¡C
µo¨¥¤H¤]«Ü¥i¼¦¡A ¦¬¨ì¤£¥¿½Tªº¸ê°T¡A ¤Ï³Q©Ç¦¨À°¥û¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G§õÁ`²Î10135593 |
µoªí®É¶¡:2023/1/3 ¤U¤È 05:33:59
²Ä 1704 ½g¦^À³
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡GCliff10135274 |
µoªí®É¶¡:2023/1/1 ¤U¤È 06:11:59
²Ä 1703 ½g¦^À³
|
°±¤î¤½¶}¥æ©ö¤F¡C ·|¤£·|¤U¿³Âd¡H¦pªG¨ó¿ì¨é°Ó¤]Ãã¥ôªº¸Ü´N·|¤U¿³Âd¡F¥i¯à©Ê¦³¦h°ª¡H¤£µL¥i¯à¡C ²{¦b°¨¤W§ä¤@®a¨Ó·í¥D¿ì¨é°Ó´N¯àÄ~Äò¦b¿³Âd¥æ©ö¡HÃø»¡¡C ¤U¦¸Y¦A«·s¥Ó½Ð¤W¿³Âd¡AÀ³¸Ó·|¬O¤@¦~«áªº¨Æ¤F¡C
¨«¨ì¤µ¤Ñ³oÓ¦a¨B¸ÓÀË°Qªº³£¸Ó³QÀË°Q¡C ¤£·QÄ~Äò¨«¤U¥hªº´N°±¤U¨Ó§a¡AÅýÄ@·N«e¶iªºÄ~Äò¨«¤U¥h¡F¤£¸ÓÄ~Äò°µ¤U¥hªº¤]¸Ó°±¤F¡Aȱo°µ¤U¥hªº¤~Ä~Äò¿N¿ú¡F©ó¤H¡B©óºÞ²z¡B©ó²£«~³£¸Ón¦n¦nÀË°Q¾ã²z¦A¥Xµo¡A¤×¨ä¦b³o·³¥½¦~ªìªºÃöÁ䶥¬q¡A·s¦~·s§Æ±æ¡A¥²µMn¥ý¯}¤~¯à¥¬·s¡C
©Ò¥Hn¿ú¤]n·s¡A¤£·|¦A¦³²Ä¤G¦¸ªº¦s¬¡¾÷·|¡Cn¦³·sªº¸êª÷¡A¤]n¦³·sªººÞ²z³W¹º«äºû¡An«Ø¥ß·sªº§Î¶H¶ì³y¡An¦A¥[±j»P§ë¸ê¤H¡B´CÅ鶡ªº·¾³q¡An¥[§ÖÁ{§É¸ÕÅç¶i«×¡K¡K
¦³¤Hı±on¥ý¦³¸êª÷¤~¯à³Ð·s¡F¦³¤H»{¬°À³¥ý³Ð·s¤~¯à§l¤Þ¸êª÷¶i¨Ó¡F¦U¦³«H¥õ¡A¦U¾Ö¨ä¥D¡FµL½×¦p¦ó¡A½Ð¤½¥q¥[¿§V¤O¡A¤@©wn¥[ªo¡A¥Í§Þ¦Ñ¹««Ëªº¯ä¦W¡]¯ä¨ý¡^¤£·|¥uÀH®É¶¡´N·|¦Û¦æ´²¥h¡I
2023·s¦~·s§Æ±æ¡G¡u½Ð¤½¥q¥[ªo!!!¡v
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¦n©_10151881 |
µoªí®É¶¡:2022/12/31 ¤W¤È 08:45:11
²Ä 1702 ½g¦^À³
|
§A²{¦b¤â¤¤¨SªÑ²¼´N¨S¦³¼W¸êªº°tÃB¡I ¤@±i¥i»{222ªÑ¡A¤â¤¤¦³ªº¸Ü¡A¥LÀ³¸Ó·|±H »{ÁÊú´Ú³æµ¹§A¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G«Ó°¶10144972 |
µoªí®É¶¡:2022/12/31 ¤W¤È 08:36:46
²Ä 1701 ½g¦^À³
|
½Ð°Ý²{¦bÁÙ¦³¿ìªk¶R¨ì¤ß®®10¤¸ªº¼W¸ê¶Ü? |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¦³¬G¨Æ10150629 |
µoªí®É¶¡:2022/12/29 ¤U¤È 02:01:31
²Ä 1700 ½g¦^À³
|
½Ð°Ý¥¼¤W¥«ªÑ²¼¶R½æ , °²¦p¦³¤H·Q¶R§Úªº©e°U³æ ¹ï¤è³z¹LþÃ䪺°T®§Ápµ¸¨ì§Ú ? |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡GZZZ10152277 |
µoªí®É¶¡:2022/12/29 ¤W¤È 09:31:15
²Ä 1699 ½g¦^À³
|
«Ü¦h¤U¿³Âd©Î¤U¥«ÂdªºªÑ²¼¨ä¹ê³£¦³¦b¥¼¤W¥«¥«³õ¤WÄ~Äò¥æ©ö¡A¥u¬O¦³¨Ç§ë¸ê¤H¤£À´¡A¥H¬°¤U¤F¤§«á´NµLªk¥æ©ö¤F¡A ©Ò¥Hè¤U¨ÓªºªÑ²¼¤@¶}©l±¾³æ¤£·|¤Ó¼öµ¸¡A³oÄÝ¥¿±`²{¶H¡A¤@¬q®É¶¡«áª¾¹D¦³ºÞ¹D¥i¥æ©ö´N·|ºCºC¼öµ¸¤F¡A Á|¨Ò¹³...¤O´¹¡B¤Ó¹q¡B¯à¤¸(²{§ï¦W¥xªd´`Àô)¡B¸g½n¯è¤Ó¡B¦³¦¨ºë±K...³£¬O¦p¦¹¡A ¦³¨ÇªÑ²¼¬Æ¦Ü«á¨Ó¤]«·s¦A«×¤W¿³Âd¤F¡A¦p¤O´¹¿n¦¨¹q¤l¡B·sÀ³§÷...³£¬O¡A °ß¤@®t§O¦b©ó¥¼¤W¥«ªºªÑ²¼ÄݶR½æÂù¤è¦Û¦æij»ù¾÷¨î¡A¥t¥~¥æ³ÎªÑ²¼®É»Ýn¦Û¦æ¶]¤@½ë¨é°Óªº¶°«OÂd¥x§@¿ì²z¡A ¤@¯ë¥¼¤W¥«ªÑ²¼¬O¯È¥»ªÑ²¼¡A¦ý¤U¿³ÂdªºªÑ²¼ªÑ¼Æ¦s©ñ¦b¦Û¤vªº¶°«O¤áÀY¤º¡A©Ò¥HÂàÅý®É±o¶]¨é°Ó§@375ªí®æ(¨p¤H¶¡ÂàÅý)¡A ¦p«áÄò¥æ³Î¦³³z¹Løʶ®¡A³o¬yµ{¥LÌ·|±Ð§A¡A¨ä¹ê¤£Ãø¡A´N¬O¥»¤Hn¶]¨é°Ó¸ûªá®É¶¡¦Ó¤w¡A ©Ò¥H¤£¥Î¹L«×¾á¤ß¡A°£«D¤½¥q¯uªºË¤F¡A§_«hªÑ²¼¤£·|µLºÝ®ø¥¢¡A³£¥i¥¿±`¶R½æ¡A»ù¦ì°ÝÃD½}¤F~ |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¦n©_10151881 |
µoªí®É¶¡:2022/12/29 ¤W¤È 09:29:26
²Ä 1698 ½g¦^À³
|
¥i¥H±¾³æ¡A§Úèè¶Ã¥´70¤¸½æ¡A ¦³¥X²{°T®§¡C¥i¥H¬Ý¨ì±¾³æµe±¡C À³¸Ó±¾³æ«á¡A¬Ý¦³¨S¦³¤H¸ò©p³sµ¸¤F¡C
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¦n©_10151881 |
µoªí®É¶¡:2022/12/29 ¤W¤È 09:11:15
²Ä 1697 ½g¦^À³
|
©p¥i¥H¦Û¤v±¾¬Ý¬Ý¡A»ù®æ¦Û¤vq¡Aµ¥¬Ý¬Ý¦³¨S¦³¤H ¥´¹q¸Ü¸ò©p³sµ¸¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤p¸ê¤k10145383 |
µoªí®É¶¡:2022/12/29 ¤W¤È 09:08:57
²Ä 1696 ½g¦^À³
|
¤µ¤Ñ®Ú¥»¨S¦³¶R³æ¡A¨S¦³³ø»ù |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¦n©_10151881 |
µoªí®É¶¡:2022/12/28 ¤U¤È 07:22:24
²Ä 1695 ½g¦^À³
|
©p·|¯uªº·Pı¤ß®®¨S¤Hn¡A³s¥D¿ìú³°Ó³£§ä¤£¨ì¶Ü¡H ¦pªG¬O¡A¤µ¤Ñ³o»ò¦n½æ«ç»ò§Ñ°O½æ¤F¡H ¤S¦pªG©p©ú¤Ñ±¾³æ¡A«Ü§Ö´N³Q¶R¨«¤F¡A¨º¦¬ªº¤H¬°¦ó¤£©È¡H ©ú¤Ñ°±¤î¶R½æ¡A·Ó²z»¡ªÑ»ù¬O¤£¬O¨S¤Hn¡A ªÑ»ùÀ³¸Ó¥u³ÑÓ¦ì¼Æ¦¬½L¤~¹ï°Ú¡H ¬°¦ó¤µ¤Ñº¦30´X¢H¡H ¤Ï¦V«ä¦Ò¬Ý¬Ý¡A·íµM³o¨S¦³«OÃÒ¤°»ò¡H §ÚÓ¤H¬O®M¨c§Ö500¸U¨S¶]°Õ¡I ¨Ñ±z°Ñ¦Ò¡K¡K³d¥ô¦Ût¡C
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G½²ºû¤¯10143700 |
µoªí®É¶¡:2022/12/28 ¤U¤È 07:16:07
²Ä 1694 ½g¦^À³
|
¡q°Ñ¦Ò¡r·N«ä¬O¥hÁA¸ÑªYÄ£¡A§ë¸ê¶RªYÄ£ªÑ²¼ªº·N«ä¡C§Ú¬ã¨s2¦~¤F¡Aı±o«Ü¤£¿ù¸ò±z±ÀÂË¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤p¸ê¤k10145383 |
µoªí®É¶¡:2022/12/28 ¤U¤È 07:09:07
²Ä 1693 ½g¦^À³
|
6634ªYÄ£¤]´¿¸g°±¤î¿³Âd¥æ©ö¶Ü¡H¬°¤°»òn°Ñ¦ÒªYÄ£©O¡H |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤p¸ê¤k10145383 |
µoªí®É¶¡:2022/12/28 ¤U¤È 07:04:28
²Ä 1692 ½g¦^À³
|
§Ú¤µ¤Ñ¦³¥´¹q¸Ü¨ì¤ß®®¤½¥q¡Aµo¨¥¤H»¡¡A3Ӥ뤺¦pªG¨S¦³§ä¨ì¥D¿ìªº¨é°Ó¡A©ÎªÌ¬O²{¦bªº¥t¥~¨âÓ¨ó¿ì¨é°Ó¤]¸ò¶iÃã°hªº¸Ü¡A¤ß®®´Nn¤U¥«¤F¡A¦pªG3Ӥ뤺§ä¨ì¤F¥Dnªº»²¾É¨é°Ó¡A´N¥i¥HÄ~Äò¦b¿³Âd¥æ©ö¡A¦pªG¤U¥«¤§«á¡AÁÙn¦Aµ¥¥b¦~¤~¯à°÷«·s´£¥X¤W¿³Âdªº¥Ó½Ð¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G½²ºû¤¯10143700 |
µoªí®É¶¡:2022/12/28 ¤U¤È 07:02:58
²Ä 1691 ½g¦^À³
|
¤p¸ê¤kY¦³¿³½ì¥i¥H°Ñ¦Ò6634ªYÄ£¡F¦³«H¤ß¤£¿ù¡A¦ýĹÁ«n¦Ût¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤p¸ê¤k10145383 |
µoªí®É¶¡:2022/12/28 ¤U¤È 06:56:59
²Ä 1690 ½g¦^À³
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G½²ºû¤¯10143700 |
µoªí®É¶¡:2022/12/28 ¤U¤È 06:51:23
²Ä 1689 ½g¦^À³
|
¤p¸ê¤k¡Gn¥ý¦b¥²´Iºô¥Ó½Ð¤@Ó¦Û¤vªº¸¹½X¤~¯à±¾¶R½æ¡AY±¾½æ¥X»ù²Å¦X¶R»ù±µªñ»ù¡A´N¦³¤H»P±z¹q¸ÜÁpô¡A¦p¦ó¥æ³Î¥L´N·|±Ð±z¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤p¸ê¤k10145383 |
µoªí®É¶¡:2022/12/28 ¤U¤È 06:45:01
²Ä 1688 ½g¦^À³
|
§Ú¬O¾á¤ß¸U¤@¨S¦³¦A¤W¿³Âd¡A¨º§Úªº¿ú¤£¬Oªw´ö¤F¶Ü¡H |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¦n©_10151881 |
µoªí®É¶¡:2022/12/28 ¤U¤È 06:41:03
²Ä 1687 ½g¦^À³
|
«ç»ò¤£·Q·Q¡A·|¦A¤W¿³Âd©O¡H¤µ¤Ñ³£´±©Ô¤F¡C ¦pªG¦A¦¸¤W¿³ÂdÀ³¸Ó¤£·|³o»òºG¤F¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤p¸ê¤k10145383 |
µoªí®É¶¡:2022/12/28 ¤U¤È 06:21:45
²Ä 1686 ½g¦^À³
|
©Ò¥H©ú¤ÑÁÙ¬O¥i¥H¶R½æÅo¡H°²¦p§Ú©ú¤Ñn½æªº¸Ü¡A¥ý¥´¹q¸Üµ¹Àç·~û¥s¥L§ä¶R¤è¶Ü¡H§ä¨ì¤F¤§«á¸ò¶R¤è½Í½×»ù®æ¶Ü¡H¦pªG¥i¥H´N¶R½æ¦¨¥æ¶Ü¡H¨º§Ún«ç»ò¼Ë§âªÑ²¼µ¹¥L¡H¥Ln«ç»ò¼Ë§â¿úµ¹§Ú¡H |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡GZZZ10152277 |
µoªí®É¶¡:2022/12/28 ¤U¤È 04:28:55
²Ä 1685 ½g¦^À³
|
¤U¿³Âd©Î¤U¥«ÂdªºªÑ²¼¡A¥²´Iºô³oÃ䪺ºô¶¤]³£ÁÙ·|¦s¦b¡A¥u¬O°Q½×°Ï·|¥Ñ¿³Âd¸õ¨ì¥¼¤W¥«±M°Ï½}¤F¡A ¦Ü©ó¶R½æªº¸Ü´N¨ì¸ÓӪѪº±¾³æ¶±¥h¡A¦P¼Ë¥i¥H±¾¶R±¾½æ¡A§ë¸ê¤H©¼¦¹¶¡¦A¦Û¦æ½Í»ù¡A «áÄò¥æ³Î¥i©e°U¥²´I±ÀÂ˪ºøʶ®ª«¬y¿ì²z¡A®¼¦w¥þ¡A¦Û¤v¨Ï¥Î¹Lªº¸gÅç¡A¨Ñ°Ñ¦ÒÅo~ |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¦n©_10151881 |
µoªí®É¶¡:2022/12/28 ¤U¤È 04:15:13
²Ä 1684 ½g¦^À³
|
¤p¸ê¤k¡A¤£¥Î©È°Õ¡K·|¦A¤W¥«ªº¡A¤½¥q¤S¨SË¡A¦A¤W¿³Âd½æ©p¤~¤£·|«á®¬¡C ºô¶¶}¤£¤F¡A´N·j´M¥²´Iºôªº¥¼¤W¥«ªÑ²¼¡A´N¦³³ø»ù¤F¡A©ú¤ÑÀ³¸Ó¤]·|¦³³ø»ù¸ê°T¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¦n©_10151881 |
µoªí®É¶¡:2022/12/28 ¤U¤È 04:07:07
²Ä 1683 ½g¦^À³
|
www.berich.com.tw/DP/Cmpinfo/cmpinfo_Price.asp?cmpname=%A4%DF%AE%AE%A5%CD%C2%E5
©ú¤Ñ¥i¥H¬Ý³o¸Ìªº³ø»ù¡An¶R½æÀ³¸Ó¥i¥H©e°U©pªºÀç·~ûÀ°©p´M°Ý¶R¤è¡H |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤p¸ê¤k10145383 |
µoªí®É¶¡:2022/12/28 ¤U¤È 01:12:40
²Ä 1682 ½g¦^À³
|
©ú¤Ñ12¤ë29¸¹¤ß®®´Nn°±¤î¿³Âd¥æ©ö¤F¡A§Ú¤â¤WÁÙ¦³¡An«ç»ò½æ©O¡H½Ö¯à°÷´£¨Ñ¥¼¤W¥«ªº½L°Óµ¹§Ú©O¡H |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡GCliff10135274 |
µoªí®É¶¡:2022/12/28 ¤U¤È 01:05:13
²Ä 1681 ½g¦^À³
|
ºô¶ÇSND13 II/III trial¥un¦A·s¦¬®×70¦W§Y¥i§¹¦¨¡F YÄݹê¡AÁÙ»Ýn¦h¤[¡H
¥ý¼á²M³o70¤H¬O¶i¤J²Ä¤G¶¥¬qªº¹ê½è¡u°Ñ»PÁ{§É¸ÕÅçÀH¾÷¤À°t¡vªº¤H¼Æ¡]¹êÅç²Õ+¹ï·Ó²Õ¡^¡A¤£¬O°Ñ¥[²Ä¤@¶¥¬qªº¡u¿zÀË¡v¤H¼Æ¡A¤]´N¬On±q¿zÀ˪º¤H¼Æ¦©±¼§t¦³¦w¼¢¾¯®ÄÀ³ªº¤H¼Æ«áªº70¤H¡C
¦¬®×¶i«×¡G 2017/5/11¡G²Ä1¤H¶i¤J²Ä¤G¶¥¬qªºÀH¾÷¤À°t¡C 2020/6/26¡G¬ù91¤H¡F²Ä¤@¦¸´Á¤¤¤ÀªR¡C 2022/8/24¡G¬ù121¤H¡F²Ä¤G¦¸´Á¤¤¤ÀªR¡C ¦¬®×³t«×¡G 2017-2020¡G90¤H/37Ó¤ë¡C¼vÅT¦]¯À¡G¦¬®×¦aÂI¦h¹è¡B¦b¼Ú¬üªºª¾¦W«×¡B¸êª÷¡C 2020-2022¡G30¦ì/26Ó¤ë¡F¼vÅT¦]¯À¡G·s«a¬Ì±¡¡B¥xÆW¥[¤J¦¬®×¦aÂI¡B¸êª÷¤À°t¡]SNB01¤À¨«¤@ªMü¡^¡C
²{¦b»Ýn¦A¼W¥[70¤Hªº¸Ü¡A¦ôpn¦Aªá¦h¤Ö®É¶¡¡H ¬ù4-4.5¦~¡H©Î4.5-5¦~¡H
¦A¥[¤W¯Ê¸êª÷ªº¼vÅT¡]¼W¸ê¯à¦¨¥\¶Ü¡H¦¨¥\«á¯à¼µ´XÓ¤ë¡H¦ó®É¥i«ì´_Ä~Äò¦¬·s®×¡HSNB01ÁÙnÄ~Äò°µ¤U¥h¶Ü¡H¡^¡A ¦A¥[¤W¡u¦pªG¡vÁÙn¤@ÓSND12©Î¥t¥~¤@Ó¤T´Áªº¸ÕÅ窺µ²ªG¨Ó¤@°_¦Ò¼{¯à¤£¯à¥Ó½ÐÃÄÃÒ¡H ³o¼ËÁÙn¦h¤[¡H
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡GBrick10141947 |
µoªí®É¶¡:2022/12/26 ¤W¤È 05:02:18
²Ä 1680 ½g¦^À³
|
¤U¿³Âd¤´¬O¦³ªÑ°È¥N²z¨é°Ó³B²zªÑªF·|³qª¾¡A¥¼¤W¥«ªÑ²¼¹L¤á¡A¼W´î¸ê³qª¾µ¥¨Æ¶µ¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¦n©_10151881 |
µoªí®É¶¡:2022/12/24 ¤U¤È 03:11:44
²Ä 1679 ½g¦^À³
|
®z®zªº½Ð°Ý¡A¨S¥D¿ìú³°Ó¡A ´²¤án«ç»ò¼W¸ê¡A ¤£¬On¦¬¨ìú´Ú³æ ¤~¯à¥h»È¦æú´Ú¡H |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¦n©_10151881 |
µoªí®É¶¡:2022/12/22 ¤U¤È 08:16:45
²Ä 1678 ½g¦^À³
|
¦¹¥Í³ÌºGªº¤@³õ´c¹Ú¡A¨¯W¥b½ú¤lªº´X¦Ê¸U ´N³o¼Ë³Q²ö¦W¨ä§®ªº·d¨ì¯}²£¡C §Ú¥Ã»··|°O±o§A̪ѪF·|¤W»¡¹Lªº ¤£¤G»ù200¤¸¡C ź¶Æ¦Û¤jªº½²¸³¨ÆªøÁÂÁ±z¡C ¹Ú¸Ó¿ô¤F¡A¤H¥Í¦³¦h¤ÖÓ¥b½ú¤l¡H
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G²q·Q10148412 |
µoªí®É¶¡:2022/12/22 ¤U¤È 12:16:05
²Ä 1677 ½g¦^À³
|
²{¦b¤½¥qªº·í°È¤§«æ , ´N¬O¼W¸ên¦¨¥\
«Øij¤½¥q²{¼W´M§ä¯S©w¤Hªº«ä¦Ò¤è¦V
½Ð¤j©@¯S©w¤H¦Y¤U¥þ³¡24¤¸ªº²{¼W ¥~¥[1¸U2000±iªº¨p¶Ò 10¤¸ , ¥H¸ÉÀv²{¼Wªº»ù®t ©Î³\¨p¶Òªº±i¼Æ©M»ù®æ¥i¥H¼u©Ê½Õ°t ¬O§_¥i¦æ ? ¦³½Ð¤½¥q°ª¼h«ä¦Ò¨Mµ¦
ÁÂÁ¤j®a !
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G«i©¹ª½«e10141841 |
µoªí®É¶¡:2022/12/21 ¤U¤È 10:51:31
²Ä 1676 ½g¦^À³
|
¬Ý¨ì³oºØ´ºªp,¦ÑªÑªF³£¤£¦n¨ü
¦ý¬O¥i¤£¥i¥H¤£n¦A·h¥X¬ì¾ÇÄѩάO±M§Q¥X¨Ó»¡¼L? ½æ±¼¤F¶Ü?
ÁÙ»¡¤£n¤ß«æ«¨! ²´«e´Nn¨S¿ú¤F,½Ö³Ì«æ? ¥D¿ì¨é°Ó«æ¶Ü? FDA«æ¶Ü? ·d²M·¡ª¬ªp¦n¶Ü? ³Ì«æªº¬OªÑªF!
³o´X¦~¨C¦¸ªÑªF·|§¹, ±Í¤H´N¹³¬Oª¯§p¤õ¨®¤@¼Ë, ¤£Â_±j½ÕºÞ²z¸gÀ窺ª¼ÂI, n¤£n¥h½Â¤å? ¦b¤UÁ¿¹L¦h¤Ö¹M¸êª÷¦¨¥», °õ¦æ®Ä²v.... «ô°U¤@¤U¦n¶Ü? ¸gÀ礽¥q¤£¬O¸gÀçLAB, ºÞ¹êÅç«Ç³»¦h¼g¼g³ø§i¥æ®t, ¸òªÑªF®³¿ú¬On¹ïªÑªFt³dªº°Ú!
§@¬°ªÑªF, §Ú̯uªº¤£»Ýn®³»¸òµÛ«ô, ¦n¦n°µªÑªF¸Ó°µªº¨Æ±¡, ºÊ·þ¤½¥q¤~¬O¥¿¹D.... |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡GAchemist10153053 |
µoªí®É¶¡:2022/12/21 ¤U¤È 08:16:02
²Ä 1675 ½g¦^À³
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¼z²´µøª÷10152715 |
µoªí®É¶¡:2022/12/21 ¤U¤È 04:52:38
²Ä 1674 ½g¦^À³
|
«z!! ´¿¸gªÑ»ù200¦hC.·sÃĪѤô¦n²` ¤£À´·sÃĤ]¤£¬O¬ÛÃöI´º§¹¥þ¤£´±¸I «ØijY¹ï·sÃĦ³·R´N¶R¬üªÑ¥Í§ÞETF©Î°òª÷
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¦n©_10151881 |
µoªí®É¶¡:2022/12/21 ¤U¤È 04:27:53
²Ä 1673 ½g¦^À³
|
¦P¼Ë¤@ÁûÃĥιï¤F¡A¥i¥H±Ï¤H ¦ý¬O¥Î¿ù¤F¡A¤@¼Ë¥i¥H±þ¤H¡K¡K ©Ç¦Û¤v¶R¤F³oÁû¬rÃÄ¡I |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤p´²¤á10147972 |
µoªí®É¶¡:2022/12/21 ¤U¤È 03:04:59
²Ä 1672 ½g¦^À³
|
¿³ÂdªÑ²¼¤ô«Ü²`¡A¬Ý¬Ý°Q½×¯d¨¥°Ï¸Ìþ¨Ç¤H¤@ª½µ¹§A§Æ±æ¡A¤S¦³þ¨Ç¤H¯¸¥X¨Ó¸Õ¹ÏÂI¿ô¤j®a |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G³Ð·s¨DÅÜ10141860 |
µoªí®É¶¡:2022/12/21 ¤U¤È 01:27:11
²Ä 1671 ½g¦^À³
|
¤½¥qªº¥D¨ÆªÌªº¤ßºA«ÜÃþ¦ü¤@®a²{¤wÂà¤WÂdªº·sÃĤ½¥q«e¦ÑªO¤@¼Ë¡A¨C¦¸Å¥¥L¶}»¡©ú·|Å¥§¹³£·|Åý¤Hı±o¤½¥qªº§Æ±æµL½a¡A¦ýÀH«á´N¬O¤£Â_ªº§ä·sÃD§÷¨Ó¿N¿ú¡A¦Ó²{¦³¤â¤WªºÁ{§É¹êÅç¤]©l²×¤û¨B¤Æ¡C¬ì¾Ç®aªº¤ßºAªGµM¸ò§ë¸ê¤H®t«Ü¦h¡A³o¸Ì¬O¸ê¥»¥«³õ¡A¦pªG¤£°È¹êªº§â¤â¤¤¬ã¨sªºÃĪ«¦¨ªG¤Æ¡A¨º»ò¡A»¡ªº¦A¤fªj¾î¸²×¨s¤]¥u¬O¬ì¾Ç¬ã¨s¹Lµ{¤¤ªºªw¼v¡C¤½¥qªº«°T´¿´£¨ì¤£¹ªÀy§ë¸êµu½u§ë¸ê¡A¦ý¹ê»Ú¤W¦³³\¦hªº§ë¸ê¤H³£¥i¤£¬O§ë¸ê¤@¡B¨â¦~¦Ó¤w¡C§Ú¦´N¤£»{¦P¥D¨ÆªÌ¹ïÁ{§É¹êÅç±À°ÊªººA«×¡A©Ò¥H§â«ùªÑ½æ¨ì¥u³Ñ5±i¡A§Ú»{¤F¡A´Nºâ¬O¥æ¾Ç¶O§a¡I§ë¸ê·sÃĤ½¥q¡A¦ÑªO¤ßºA°È¤£°È¹ê¯uªº«Ü«n¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¦n©_10151881 |
µoªí®É¶¡:2022/12/21 ¤W¤È 11:59:05
²Ä 1670 ½g¦^À³
|
ÀqÀq§ë¸ê¤ß®®±Nªñ5¦Ê¸U¡A·d¨ì²{¦b³Ñ´X¤Q¸U¡A §Ú¦Û§@Ä^¬¡¸Ó¡A¤ß®®ªº¸gÀçªÌ¡A ±z̺NºN¦Û¤vªº¨}¤ß¡A ±z̹ï±o°_§ë¸ê±z̪ºªÑªF¶Ü¡H
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¦n©_10151881 |
µoªí®É¶¡:2022/12/21 ¤W¤È 11:38:53
²Ä 1669 ½g¦^À³
|
¤@®a¤½¥q¥i¥H±q¤W¿³Âdnµo©ú·sÃıϤHªº¤½¥q¡A¸gÀç¨ì²{¦b³ÑÓ¦ì¼Æ¡AÅÜ®`¦º¤@°ï§ë¸ê¤Hªº¤½¥q¡A¸gÀçºÞ²zªÌ¤£·|ı±o«Ü¥i´d¡A«Ü¿Ø¨ë¶Ü¡H¥v§V¤ñ¦pªG§AÁÙ¯à¼g¹q¤l³ø¡A¤£ª¾¹D±z·|¹ï§Ú̳o¨ÇŪªÌ¡A¦³¤°»ò¸Ün»¡ªº¶Ü¡H¦Ó¥B±zÁÙ¬O³o¤½¥qªº°ÆÁ`¡A±z¦³¸Ü¹ï§ÚÌ»¡¶Ü¡H¤@Ó¥i¼¦ªº§ë¸êªÌ¯u·Qťť±z»¡¤°»ò¡H |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡GABC10134671 |
µoªí®É¶¡:2022/12/20 ¤U¤È 07:45:13
²Ä 1668 ½g¦^À³
|
³£n§â¤pªÑªF§Ú·d¨ìºë¯«¤Àµõ¤F |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G²q·Q10148412 |
µoªí®É¶¡:2022/12/20 ¤W¤È 08:07:56
²Ä 1667 ½g¦^À³
|
ªB¤ÍªºÆ[ÂI
¤j®aºÉ¬O´dÆ[ , §ÚÌ´N¥H³ÌÃa±¡ªp¨Ó¦ô¶q °²¦p¤ß®®Ë³¬¯}²£²Mºâ ¤ß®®ªºt¶Å , ¨Ì111²Ä¤G©ut¶Åªí¥u¦³ 46,785 ¤d¤¸·s¥x¹ô µM¦Ó¤ß®®ªº¸ê²£ ¦hÓ¾AÀ³¯gªº¬ü°êFDAÁ{§ÉÃĪ« , ¥B¦³ªº¤w¶i¤J¤T´Á ¦hӨ㦳±M§QªºÁ{§É«e¤Æ¦Xª« ³Ìªñ½²¸³Àò¬ü°ê°ê®aµo©ú®a°|¤hºa»Î ¬O§_¤]·t¥ÜµÛ¤ß®®±M§Q©Ò³sµ²ªº·sÃÄ , Yµo®i¦¨¥\¥i¯à¹ïªÀ·|°^Ämªº»ùȪ֩w ¥~¥æ³¡¤]µo¤å¯¬¶P www.roc-taiwan.org/uslax/post/33778.html
¯à¤£¯à¨ÌKaruna ªº¥«È©ÎªÌ¹L¥hºë¯«¯«¸gÃĪ«±ÂÅvªº»ù½X¨Ó°Ñ¦Ò¦ô¶q ¨ì©³¤ß®®È¤£È³oÓ»ù ? ½²¸³À³¸Ó¨S¨p¤ß , ¦Ó¥Bn¤£¤ß«æ , ¦n¦n½Í
³o¼Ëªº»¡ªk , ½Ð±Ð¤j®a¦³¨S¦³ª¼ÂI©M¤@´[±¡Ä@ ?
¶È¨Ñ°Ñ¦Ò ! ÁÂÁ¤j®a !
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡GABC10134671 |
µoªí®É¶¡:2022/12/13 ¤U¤È 07:53:05
²Ä 1666 ½g¦^À³
|
¤j®a·|»{»{¶Ü? ¤jªÑªFÀ³±aÀY»{§a
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G²q·Q10148412 |
µoªí®É¶¡:2022/12/13 ¤U¤È 06:53:29
²Ä 1665 ½g¦^À³
|
¤@±ø±Ï¥Í°é ?
¤½¥q¹w¦ôªº²{ª÷¬y¶q , ¨ì112¦~1 ¤ë©³©|¾l¤d¸U¥x¹ô ²{¦b§Ú̫ܩȲ{ª÷¼W¸ê»{Áʤ£¨¬ , §Î¦¨¸êª÷¶Ò¶°¥¢±Ñ ¤µ¤Ñ§ä¤F¤@¤U¤Èªºªk³W , §ä¨ì¤@±ø±Ï¥Í°é ? ´N¬O¸gÀÙ³¡°Ó¤u¦æ¬Fªk³W , ¹ï©ó [ ¤½¥qªk ] ²Ä276±øªº¨çÄÀ gcis.nat.gov.tw/elaw/lawDtlAction.do?method=lawToCons&pk=19&art=276&dash=0
ªk³W¦WºÙ¡G ¤½¥qªk ªk³W¤å¸¹¡G ¤¤µØ¥Á°ê110¦~12¤ë29¤éµØÁ`¤@¸g¦r²Ä11000115851¸¹ µo¥¬¤é´Á¡G 110¦~12¤ë29¤é
¡]¶Ê§i»PºM¦^»{ªÑ¡^ ²Ä276±ø µo¦æ·sªÑ¶W¹LªÑ´Úú¯Ç´Á¡A¦Ó¤´¦³¥¼¸g»{ÁʩΤw»{ÁʦӺM¦^©Î¥¼ÃºªÑ´ÚªÌ¡A¨ä¤w»{ÁʦÓú´Ú¤§ªÑªF¡A±o©w¤@Ó¤ë¥H¤W¤§´Á¡A¶Ê§i¤½¥q¨Ï»{Áʨ¬ÃB¨Ãú¨¬ªÑ´Ú¡F¹O´Á¤£¯à§¹¦¨®É¡A±oºM¦^»{ªÑ¡A¥Ñ¤½¥qªð¦^¨äªÑ´Ú¡A¨Ã¥[µ¹ªk©w§Q®§¡C ¦³¦æ¬°¤§¸³¨Æ¡A¹ï©ó¦]«e¶µ±¡¨Æ©ÒP¤½¥q¤§·l®`¡AÀ³t³s±a½ßÀv³d¥ô¡C ¨çÄÀ¤º®e¡G
________________________________________ ¡µ»{ªÑú´ÚªÑªF¤§°h´Ún¥ó ¨Ì¤½¥qªk²Ä276±ø²Ä1¶µ³W©w¡G¡uµo¦æ·sªÑ¶W¹LªÑ´Úú¯Ç´Á¡A¦Ó¤´¦³¥¼¸g»{ÁʩΤw»{ÁʦӺM¦^©Î¥¼ÃºªÑ´ÚªÌ¡A¨ä¤w»{ÁʦÓú´Ú¤§ªÑªF¡A±o©w1Ó¤ë¥H¤W¤§´Á¡A¶Ê§i¤½¥q¨Ï»{Áʨ¬ÃB¨Ãú¨¬ªÑ´Ú¡F¹O´Á¤£¯à§¹¦¨®É¡A±oºM¦^»{ªÑ¡A¥Ñ¤½¥qªð¦^¨äªÑ´Ú¡A¨Ã¥[µ¹ªk©w§Q®§¡C¡v·Ç¦¹¡A¨ãÅéӮצp²Å¦X¤W¶}³W©w¤§n¥ó¡A¤w»{ÁʦÓú´Ú¤§ªÑªF¡A¦Û±oºM¦^»{ªÑ¡An¨D°h¦^ªÑ´Ú¡C¤½¥q°h¦^ªÑ´Ú¡A¤½¥qªk©|µL³W©wÀ³¸gªÑªF·|©Î¸³¨Æ·|¨Mij¡C¦Ü¸g²z¤H¥i§_À³ªÑªFn¨D³w¦Û°h¦^ªÑ´Ú¤@¸`¡A¤¹Äݤ½¥q¦Ûªv¨Æ¶µ¡A¨Ì¤½¥q¤º³¡µ{§Ç¿ì²z¡C±©¨ãÅéӮסA¤´©y¥Ñªk°|¥»¨ä½T«H¤§ªk«ß¨£¸Ñ¡A¼f°uµô§P¡C ¡]¸gÀÙ³¡94¦~4¤ë4¤é¸g°Ó¦r²Ä09402039170¸¹¨ç¡^
¡µ¤½¥q¿ì²z¼W¸êµo¦æ·sªÑÅܧóµn°OºÃ¸q ¤@¡B«ö¤½¥qªk²Ä276±ø²Ä1¶µ³W©w¡G¡uµo¦æ·sªÑ¶W¹LªÑ´Úú¯Ç´Á¡A¦Ó¤´¦³¥¼¸g»{ÁʩΤw»{ÁʦӺM¦^©Î¥¼ÃºªÑ´ÚªÌ¡A¨ä¤w»{ÁʦÓú´Ú¤§ªÑªF¡A±o©w1Ó¤ë¥H¤W¤§´Á¡A¶Ê§i¤½¥q¨Ï»{Áʨ¬ÃB¨Ãú¨¬ªÑ´Ú¡F¹O´Á¤£¯à§¹ ¦¨®É¡A±oºM¦^»{ªÑ¡A¥Ñ¤½¥qªð¦^¨äªÑ´Ú¡A¨Ã¥[µ¹ªk©w§Q®§¡C¡v·Ç¦¹¡A¨ãÅéӮצp²Å¦X¤W¶}³W©w¤§n¥ó¡A¤w»{ÁʦÓú´Ú¤§ªÑªF¡A¦Û±oºM¦^»{ªÑ¡An¨D°h¦^ªÑ´Ú¡]¥»³¡94¦~4¤ë4¤é¸g°Ó¦r²Ä09402039170¸¹¨çÄÀ°Ñ·Ó¡^¡C¦X¥ý±Ô©ú¡C ¤G¡B¦¸«ö¤½¥qªk²Ä266±ø³W©w¡A¤½¥q¿ì²zµo¦æ·sªÑ«YÄݸ³¨Æ·|¤§Â¾Åv¡AÀ³©ú½Tq©úµo¦æ·sªÑª÷ÃB¡BªÑ¼Æµ¥¡CÕ¤½¥qµo¦æ·sªÑ»{ú¤£¨¬PµLªk©ó¼W¸ê°ò·Ç¤é§¹¦¨ªÌ¡A¥ç±o¥l¶}¸³¨Æ·|¨Mijץ¿µo¦æ·sªÑ¼ÆÃB¤Î¼W¸ê°ò·Ç¤é¡A¥H¹ê»Ú¤w»{ÁÊú´Ú¤§ª÷ÃB¿ì²z¡A©óªk©|µL¤£¥i¡C ¡]¸gÀÙ³¡105¦~1¤ë28¤é¸g°Ó¦r²Ä10502005270¸¹¨ç¡^
½Ð¤j®a§â«ÂI©ñ¦b ¡§ ¤G¡B¦¸«ö¤½¥qªk²Ä266±ø³W©w¡A¤½¥q¿ì²zµo¦æ·sªÑ«YÄݸ³¨Æ·|¤§Â¾Åv¡AÀ³©ú½Tq©úµo¦æ·sªÑª÷ÃB¡BªÑ¼Æµ¥¡CÕ¤½¥qµo¦æ·sªÑ»{ú¤£¨¬PµLªk©ó¼W¸ê°ò·Ç¤é§¹¦¨ªÌ¡A¥ç±o¥l¶}¸³¨Æ·|¨Mijץ¿µo¦æ·sªÑ¼ÆÃB¤Î¼W¸ê°ò·Ç¤é¡A¥H¹ê»Ú¤w»{ÁÊú´Ú¤§ª÷ÃB¿ì²z¡A©óªk©|µL¤£¥i¡C¡¨
¤]´N¬O»¡ Y»{Áʤ£¨¬®É , ¤½¥q¸³¨Æ·| ¡§±o¥l¶}¸³¨Æ·|¨Mijץ¿µo¦æ·sªÑ¼ÆÃB¤Î¼W¸ê°ò·Ç¤é¡A¥H¹ê»Ú¤w»{ÁÊú´Ú¤§ª÷ÃB¿ì²z¡K¡¨
©Ò¥H½Ð¦³»{Áʸê®æªºªÑªFÌ¿ãÅD»{ªÑ , ¦Ü¤ÖÅý¤½¥q¹F¨ì¤@Ó¥i¸ê©µÄò¹B§@ªºª÷ÃB ¦P®É½Ð¤½¥q¦b¸êª÷³W¹º®É , À³´£¦¶Ò¸ê§@·~ , ¤£nÅý¤½¥q¦³¸êª÷Â_ª¤ªº·ÀI
ÁÂÁ¤j®a !
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡GABC10134671 |
µoªí®É¶¡:2022/12/13 ¤U¤È 01:05:53
²Ä 1664 ½g¦^À³
|
¤ß®® 110¦~ªºÀç·~¶O¥Î¤ä¥X¬°3.15»õ 111¦~¤W¥b¦~Àç·~¶O¥Î¤ä¥X¬°1.63»õ ¦Ó111¦~¤W¥b¦~±b¤W²{ª÷¥u³Ñ¬ù1.5»õ ´«¨¥¤§¡A¨ì¥»¤ë¤½¥qªº²{ª÷´N¿N§¹¡A³sµoÁ~¤ô³£¦³°ÝÃD©O¡H ¦³µL¤F¸Ñªº¥ý¶i¡A¥i¥H¸Ñ´b¤@¤U¡H ------------------------------------------------------------------ ¤µ¤Ñ¦³¤½§i¡A¤j®a¦³¦ó¬Ýªk
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G²q·Q10148412 |
µoªí®É¶¡:2022/12/13 ¤W¤È 06:57:05
²Ä 1663 ½g¦^À³
|
ÁÂÁ Cliff¤j®¦¼wªº¸Ñ»¡©M¶}ÄÀ Åý¤j®a¹ï©ó¤½¥qªº²£«~½u¦³§ó²`ªº»{ÃÑ ·PÁ±z ! ! |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡GCliff10135274 |
µoªí®É¶¡:2022/12/12 ¤W¤È 10:59:42
²Ä 1662 ½g¦^À³
|
¶W¯Å¾Ç¦WÃÄ(Supergenerics; Hybrid Generics)¡H¡H
2018/09/10·s»D½Z¡G¡u°£¤FSND, SNG, SNA¡A¤ß®®¥ÍÂåSNS¨t¦C²£«~Àò¤¤µØ¥Á°ê¡B¬ü°ê±M§Q®Öã¡v 2018/12/31«°T¡G¸³¨Æ·|¨Mij´£½ÐªÑªF·|±ÂÅv»PSyneuRx Neuroscienceñq±M§QÅv±ÂÅv«´¬ù 2019/02/27«°T¡GªÑªFÁ{®É·|¨Mij±ÂÅv¸³¨Æ·|»PSyneuRx Neuroscienceñq±M§QÅv±ÂÅv®× 2019/03/18«°T¡G¸³¨Æ·|¨Mij»PSyneuRx Neuroscienceñq±M§QÅv±ÂÅv¦X¬ù®× 2020/12/23«°T¡G¸³¨Æ·|¨Mij¸Ñ°£»PSyneuRx Neuroscienceªº±M§QÅv±ÂÅv¦X¬ù
¦b2018/09/10·s»D½Z¤¤´£¨ì¡G ¡u¤ß®®¥ÍÂå(6575 TT)¤µ¤Ñ«Å¥¬¨äSNS¨t¦C²£«~¤é«e¤ÀÀò¤¤µØ¥Á°ê¸gÀÙ³¡´¼¼z°]²£§½¡B¬ü°ê±M§Q°Ó¼Ð§½¤§±M§Q®Öã³qª¾¡A±M§Q¦WºÙ¬°¡u¥Î¥HªvÀø¤¤¼Ï¯«¸g¨t²Î¯e¯f¤§¥]§tf¥Ò»ÄÆQ¤Æ¦Xª«¤ÎÂý»Äªº²Õ¦Xª«¡v(Compositions Containing Benzoate Compound and Tannic Acid for Treating Central Nervous System Disorders)¡A¥»µo©ú«Y´£¨Ñ¤@ºØ²Õ¦Xª«¡A¥H¤Î¸Ó²Õ¦Xª«¥Î©óªvÀø¤¤¼Ï¯«¸g¨t²Î¯e¯fªº¥Î³~¡C ¤¤¼Ï¯«¸g¨t²Î¯e¯f¬Û·í½ÆÂø¦Ó¤£©ö²z¸Ñ¡A¹O¥b¥@¬ö¥H¨Óºë¯«¯e¯fÃĪ«¶}µo¦h«]¦b³æÓi¯«¸g¶Ç¾É¡AP¨Ï¸Ó»â°ìÃĪ«Àø®Ä¤´¥¼¿²²z·Q¡F¯f¤H©¹©¹»Ýn¦P®ÉªA¥Î¦hºØÃĪ«¡A¥B¸g±`¦]¬°ÃĮĤ£¨Î»P¤£¨}¤ÏÀ³¦Ó´À´«ÃĪ«¡A³o¨Ç§¡ÄY«°§C¥ÎÃÄ¿í±q©Ê¡A¼W¥[¯e¯f´_µo©Î´c¤Æªº·ÀI¡C¤ß®®¥ÍÂå°£¤F«ùÄò±q¤W¦ì®Ú·½©ÊªºNMDA¾÷Âà¶}µo¼s®Äªº³Ð·sªvÀø¥~¡A¥tµo²{SND5¨ã¦³¼W±jSND1ªº®ÄªG¡A§Y¦P®É¬I¤©§C¾¯¶qªºSND1»PSND5«K¥i¹F¨ì©Î¶W¶V°ª¾¯¶qSND1ªº®ÄªG¡A¹EµÛ¤â¬ãµo¬J¦³¤¤¼Ï¯«¸gÃĪ«»PSND1¡BSND5¶i¦æ²Õ¦Xªº¥i¦æ©Ê¡C ¡@¡@SNS¨t¦C²£«~ÄÝ©ó·s¤À¤l¹êÅé (New Molecular Entities)¡A³z¹L§ÚÌ¿W¦³ªº§Þ³N§ïµ½ÃĪ«µ²ºc¡B²Õ¦X¡A¦Ó§ó¦³§Q©óÃĪ«ªº§l¦¬¤ÎÀø®Ä¡A¦¹©úÅã§O©ó¤@¯ë¾Ç¦WÃÄ¡AºÙ¤§¬°¶W¯Å¾Ç¦WÃÄ(Supergenerics; Hybrid Generics)¡C¤ß®®¤@ª½»{¬°¡A¦³ÃĪ«µS¦p¶È¬°¯f¤H¸Ë¸m¤F³æ½ü¡A¦æ¤£Ã¥ç¨«¤£»·¡A¬O¬G¤ß®®P¤O¬°¯f¤H³Ð³y¥t¤@Ó½ü¤l(Invent the Other Wheel)¡A¡K¡K¡K(¥H¤U²¤)¡v
±q¤W±³o¬q·s»D½Z¤º®e¨Ó¬Ý¡ASupergenerics¤w¤£¬O»»»·ªº·sµo©ú¡A¥u¬O¤@Ó¤½¥q·s³]ªº·s¦Wµü¡A©Ò³sµ²ªº±M§Q´N¬O2018/02/08¬ü°ê±M§Q¾÷ºc¤½¥¬ªºUS 20180036267¡uCompositions Containing Benzoate Compound and Tannic Acid for Treating Central Nervous System Disorders¡v¡A»P¬Q¤é¶K¤åµù1ªº¡u2018/10/23-¤ß®®¬ü°ê±M§Q¡GUS 10,105,378 B2¡v¦³¬Û·íµ{«×ªº¬ÛÃö©Ê¡]µù1ªº±M§Q¤º®e§ó¸Ô²Ó¡^¡A¤]´N¬O»¡¡A³oÓ¡uSupergenerics¡v¦´N¬OSND13ªº¤º²[¡A¥u¬O¨ì¤F2018/12/31®M¤WSupergenerics¤§¦W±ÂÅvµ¹¡uSyneuRx Neuroscience¡v¡A¦Ó²{¦bSyneuRx Neuroscience¤w¡K¡K
¡u¤ß®®¬O§_¤w½m´N [ ¶W¯Å¾Ç¦WÃÄ ] ªº»s³Æ¥B§¹¦¨°Êª«ªº¸ÕÅç ?¡v ¬Q¤é¶K¤åµù1ªº¡u2018/10/23-¤ß®®¬ü°ê±M§Q¡GUS 10,105,378 B2¡v¡A¾ã¥÷±M§Q¤º®e³£¦b°Q½×¤p¹«¹êÅ窺µ²ªG¡A¦Ó¥B¸ÓÃĤwÀ³¥Î¦bSND13¶i¦æphase II/IIIÁ{§É¸ÕÅç¡A¸Ó¸ÕÅç¤w©ó2022/08/24§¹¦¨²Ä¤G¦¸´Á¤¤¤ÀªR¡A¥B¤½§i«°T¡G¦w¥þºÊ´ú©eû·|«Øij¡AÄ~Äò¶i¦æÁ{§É¸ÕÅç¡A¤£°µ¥ô¦ó½Õ¾ã¤H¼Æ¡C¡K¡K
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡GCliff10135274 |
µoªí®É¶¡:2022/12/11 ¤U¤È 09:23:55
²Ä 1661 ½g¦^À³
|
SNB01 ®Ú¾Úºô¸ô¬d¨ìªº³æ¹ç»Ä-¼W¯q¤èªkªº¬ü°ê±M§Q¤å¥ó¡]µù1¡^±oª¾¡A¥ÑÆQ½§¤ì¡]Rhus Chinesis«~ºØ¸û¨Î¡^²£¥Íªº¤¿¤l¡]¨¤¿Àu©ó¨{¿¡F3-4¤½¤À¤j¤p¬°¨Î¡^¥H§t¦³¤Ógalloyl moieties¡]5G¡^¥H¤WªÌ¦b¤p¹«¹êÅ礤®i²{¸û¨ÎªºDAAO§í¨î¯à¤O¡A¥Bgalloyl moieties§t¶q¶V°ª¡A§í¨îDAAO®ÄªG¶V¦n¡]IC50¶V§C¡^¡C©Ò¥H¦b»s³Æ³æ¹ç»Äªº¹Lµ{¤¤·|¥ý¥h±¼4G ªº¦¨¤À¡AµM«á¸g¹L¿i¯»¹LÂo¦¨²Ó¯»ª¬¡A¦A¸g¹L·»¾¯·»¸Ñ¡C³o·»¾¯·|¬O¤þ଩Î2-¤B଩ΤA»Ä¤Aà©Î¤A¾J¡]°sºë¡^µ¥¡F¤£¦Pªº·»¾¯¨Ï¥Î·|²£¥X¤£¦P¯Â«×³y¦¨¤£¦PªºIC50¡C±µ¤U¨Ón¸g¹L¨â¹DµÑ¨ú¤âÄò´£°ª¯Â«×¡C²Ä¤@¹DºÒ»Ä¹[/¤ì¬´/²¸»ÄÁâ¡F²Ä¤G¹D¸g¹L¤þà¬/¤vÖJ¦¨¬°²GºA¡C¦A¸g¹L¤þà¬/¤G´â¥ÒÖJ«á¦¨¬°©TºA¡AµM«á¦A¼ßªd¤Æ¡K¡K¦¨¬°°ª¯Â«×ªº³æ¹ç»Ä¡]1-4G§t¶q§C©ó2%¡^¡C ¬°¦ón¸g¹L³o¨â¹DµÑ¨ú¤âÄò¡H¦]¬°¤p¹«¹êÅçÅã¥Ü¥h°£4G¦¨¤À¤Î¸g¹L²Ä¤G¹DµÑ¨ú«á²£ª«¨ã¦³¸û¨Î(§C)ªºDAAO IC50È¡C ¥¼¨Ó¤è¦V¡G¨«¤¤ÃÄ¡H«O°·¹«~¡H ¥i¬O²{¦b§â³o¼ËµÑ¨ú«áªºì®Æ¥Î©óSNB01¡A³o¼ËªºµÑ¨ú©Ò¥Î¤èªk¡B©Ò±o¦¨¤À¯à§_²Å¦X¤¤ÃĪk³Wªºn¨D¡H¡]µù2¡^«O°·¹«~©O¡H¡]µù3¡^ ¨«¦èÃÄ¡H SNB01¤G´ÁÁ{§É¸ÕÅ窺³]p¬O¥H¨ü¸ÕªÌªA¥ÎÃĪ««áÅ餺¯f¬r¶qÅܤƧ@¬°¥DnÁ{§É«ü¼Ð¡A¦b¨ü¸Õªº²Ä3¡B7¡B10&14¤Ñ³£·|±ÄÀËÅç¯f¬r¶q¡]quantification of the viral genome¡^¡F¦ý¦b¸Ñª¼ªº¦h¦¸«°T¤¤§¡¥¼´£¤Î³o¶µ¼Æ¾Ú¡A¥H¥|¦¸«°Tµo¥¬ªº·®æ¨Ó²q´ú¡A³o¤@¶µ«ü¼ÐÀ³¸Ó¬OºÉ¾¥¡A§_«h¦´N¤½¥¬¤F¡C¦pªG¦¹±À½×¦¨¯u¡A¨ºSNB01ªºMOA¡]mechanism of action¡^«ç»ò¿ì¡H¾¯¶q¦³¨S¦³°ÝÃD¡HÁÙ¦³¡AµÑ¨ú°ÝÃD¥¼¨ÓY¶i¤J¤T´Á«áCMCªº°ÝÃD«ç¸Ñ¡H¡]§å§å²£«~ªº¯Â«×µLªk¤@P¡^
³Ì«nªº¬O¡A±q¤@¶µ°ê¤º¦Û¤µ¦~¤¤ë©³¶}©lªº¤C¦Ê¦h¦ì·s«a¯f¬r»´¯g½T¶EªÌ½u¤W·ÓÅ@¸gÅç¨Ó¬Ý¡A¬Ý¤£¨ì»´¯gªÌ¯S§O¥ÎÃĪº¥«³õ¡C»´¯g½T¶EªÌ¥u»ÝªA¥Î¸ò¤@¯ë·P«_¥ÎÃÄ´X¥G¬Û¦Pªº¯gª¬½w¸ÑÃĪ«¡A¦A¥[¤W¤¦Ü¤C¤Ñªº¥ð®§¹jÂ÷¡A«K¯à¶¶§Q¦^¨ì¤u§@±^¦ì¡C¤C¦Ê¦h¦ì»´¯g½T¶EªÌ·í¤¤¶È¦³¤@¦ì80·³¨ã¦³¤T°ª¤ÎºC©ÊµÇ¯fªºªøªÌ»Ý¦í°|¶i¤@¨B¥[±j·ÓÅU¡A¨ä¾lªº±wªÌªA¥ÎÃþ¦ü·P«_ÃĪº³B¤è«á¡A§Ö«h¦bµo¯f4¤Ñ«á¡AºC«h¦bµo¯f8-9¤Ñ«á´N§Ö¿zÂà³±¤F¡A³»¦h¦³¨Ç¤H¦bµo¯f2-4¤Ñ¤º¥i¯à·|¸g¾ú´X¤Ñ³ïÄV«Üµhªº§xÂZ¡A¨º´N¦A¥[¤W¤@²~³ïÄV¼Q¾¯´N¥i·d©w¡]µù4¡^¡C¥xÆW¥Á²³ºâ¬O¤ñ¸ûÄ@·NªAÃĪº¤]¤£¹L¦p¦¹¡A¨ä¥L¼Ú¬ü¦a°Ï§ó¬Ý¤£¥XÄò§@¤T´Áªº»´¯gªÌ¥ÎÃÄ¥«³õ¦bþ¸Ì¡H
SND13 ³æ¹ç»Äªº¦¨¤ÀÁÙ³Q¥Î©óSND13·í½á§Î¾¯¡]Ãĥλ²®Æ¡^¡A¦ý¨Æ¹ê¤W¬O§Æ±æ¥¦¯à¼W¥[Àø®Ä¡A²{¦b¦³ÂI¾á¤ß¥¦·|¤£·|¦pÄ@¦aµo´§¥[¦¨ªºÀø®Ä¡H
¥t¥~2022/10/20¬ü°êFDA¾Ú»¡¦]¬°2021/7¤ë®ÖãªvÀøªü¯÷®üÀq·sÃÄAduhelm¡]aducanumab¡^©Ò±a¨Óªºª§Ä³¡]µù5¡^¦Óµo¥¬¤F¡uÁ{§É¸ÕÅ礤ªº¦h«²×ÂI¡X¥ø·~«ü¤Þ¡v¡]Multiple endpoints in clinical trials ¡Vguidance for industry¡^¡A³o¹ï¥¼¨ÓSND13°µ§¹¤G/¤T´ÁÁ{§É¸ÕÅç«á¯à§_ª½±µ¥Ó½Ð¨ìÃÄÃÒ·|µo¥Í¼vÅT¡C½²¸³¤w¦b2022/10/25ªº»¡©ú·|¤W³Q°Ê¦a¦^µª¤F³o¶µªÑªFªº´£°Ý¡A¤@¨Ó¨ì®ÉÔn¬Ý¸ÕÅç¼Æ¾Ú°÷¤£°÷¦n¡F¤G¨Ó«OÀI°_¨£³Ì¦n¦A¥[¤W¥t¤@ÓÁ{§É¸ÕÅç¼Æ¾Ú¥H¨¾¸U¤@(¥[§ÖSND12¦¬®×¶i«×¡H©Î¥t¥~«°_¤@Ó·sªºSND13Á{§É¸ÕÅç¤ñ¸û§Ö¡H)¡C SND12¡BSND13¡Gsingle primary endpoint SNG12¡Gco-primary endpoints¡]depression & suicide prevention¡^
¥H¤U¸`Ķ¡G¡uMultiple endpoints in clinical trials ¡Vguidance for industry¡v¡]www.fda.gov/files/drugs/published/Multiple-Endpoints-in-Clinical-Trials-Guidance-for-Industry.pdf ¡^ ¡uÁ{§É¸ÕÅ礤ªº¦h«²×ÂI¡X¥ø·~«ü¤Þ ·§½×¡G ¦b¤@ÓÁ{§É¸ÕÅ礤¤ÀªR¤£¥u¤@ÓªºÁ{§É²×ÂI¡]¦h©ó¤@ÓÁ{§É²×ÂI¡^®É¡AY¥¼¹ï¦h«©Ê¡]multiplicity¡^°µ¥X½Õ¾ãªº¸Ü¡A¥i¯à·|¼W¥[¡]¥Ñ³o¤@өΦh©ó¤@Ó²×ÂI©Ò¾É¤Þ¥Xªº¡^¿ù»~ÃĮĵ²½×ªº¾÷·|¡C ¤@¯ë¦Ó¨¥¡AFDAªº¥ø·~«ü¤Þ¨Ã¥¼«Ø¥ßªk«ß±j¨î°õ¦æªº³d¥ô¡C¬Û¤Ï¦a¡A¥u¬O±Ôz¤F¥DºÞ·í§½¥Ø«e¹ï¤@¨ÇijÃDªº¬Ýªk¡A¥¦À³¸Ó³Qµø¬°¥u¬O¤@ºØ«Øij¡]recommendations¡^¡A°£«D¤Þ¥Î¤F¯S§Oªºªk³W©Îªk©wn¨D¡C ¦b«ü¤Þ¤¤©Ò¨Ï¥Îªº¡uÀ³¸Ó¡v¡]should¡^ªí¥Ü©y¡K¡]suggested¡^©Î«Øij¡]recommended¡^¡A¦Ó¤£¬O«D¨ã³Æ¤£¥i¡]required¡^¡C I´º»P½d³ò¡G Àø®Ä²×ÂI¡]efficacy endpoints¡^¬O¤@¨Ç³Q³]p¥Î¨Ó¤Ï¬MÃĪ«¹w´ÁÀø®Äªº±¹¬I¡C ¥¦¥i¥H¬OÁ{§É¨Æ¥óªºµû¦ô¡]P¦º²v¡B¤¤·¡BªÍ³¡´c¤Æ¡BÀR¯ß¦å®êµ¥¡^¡A©Î¬O¯gª¬¡]µh¡B³Ý¡B¼~Æ{¯gª¬¡^¡A©Î¥\¯àªºµû¦ô¡]¨B¦æ©Î¹B°Êªº¯à¤O¡^¡A©Î¬O¥i³Q¦X²z¹w´Á¨Ó¹w´úÁ{§É®Ä¯qªº¥N²z«ü¼Ð¡]surrogate endpoints¡^¡C ¦]¬°¤j¦h¼Æ¯e¯f¬Ò¦³¤Þ°_¶W¹L¤@¶µÁ{§É¨Æ¥ó¡B¯gª¬¡B¤Î/©Î§ïÅÜ¥\¯àªº¼ç¤O¡A¦]¦¹«Ü¦hÁ{§É¸ÕÅç³Q³]p¥H¯e¯fªº¦hÓ±¦V¨ÓÀ˵øÃĪ«Àø®Ä¡C¦b¬Y¨Ç±¡ªp¤U¡AµLªk®Ú¾Ú³æ¤@¯e¯f±¦V¨Ó¥R¤À½T©wÀø®Ä¡A¨º»òÁ{§É¸ÕÅçÀ³±N¯e¯fªº¦hÓ±¦V¯Ç¤J³æ¤@Á{§É²×ÂI¡A©Î¥H¦h«Á{§É²×ÂI(multiple endpoints)¨ÓÃÒ©ú®ÄªG¡C ¦Ó¦b¨ä¥Lªº¤@¨Ç±¡ªp¤U¡A´XÓÁ{§É²×ÂI¤¤ªº¥ô¦ó¤@Ó²×ÂIªº®ÄªG¥i¯à¨¬¥H¤ä«ù¤W¥«ÃÄÃÒªº¥Ó½Ð§åã¡C Y¤@ÓÁ{§É¸ÕÅ礤¦³¦hÓÁ{§É²×ÂI¦ý«o¥¼¯à¦Ò¼{¨ä¦h«©Ê®É¡A´N·|¼W¥[°µ¥X¿ù»~ÃĪ«Àø®Äµ²½×ªº¾÷·|¡C¡]µù : FDA¾á¤ß·|¦]¦¹¼W¥[°°¶§©Êªº¾÷²v¡Ftype-I error¡^ ¥DºÞ·í§½¦b·Nªº¬O¦h«©Ê¬O¨Ó¦Û©ó¥Î¨Ó¤ä«ùÅã¥ÜÃĪ«Àø®Ä¥HÃÄÃҥӽФÎFDA§å㪺¥é³æªºÁ{§É¸ÕÅ窺µû¦ô¡AµM¦Ó¡A³oÓijÃD¹ï³e¬ï¾ãÓÃĪ«¬ãµoªºÁ{§É¸ÕÅç¬O«nªº¡C ¨Ò¦p¡A¦pªGn³q¹L°²³]ÀËÅç¨Óµû¦ô¦w¥þ©Ê¡A«h¥¦Ì±N¨ü¨ì¥»«ü«n¤¤´yzªº¦h«©Ê¦Ò¼{¦]¯Àªº¨î¬ù¡C¦w¥þ©Ê¤ÀªRªº¦h«©Ê°ÝÃD¤£Äݩ󥿦¡²Îp´ú¸Õªº¤@²Õ¹w¥ý«ü©wªº°²³]¡A¤£¦b¥»«ü«nªº½d³ò¤º¡C¡v ¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡]³Ñ¤Uªº½Ð°Ñ·Óì¤å³sµ²¡^
·í°È¤§«æ ¥©°üÃø¬°µL¦Ì¤§ª¤¡A®a¤¤¦Ì¬û§Ön¨£©³¤F¡C µL¦Ë¥O¤H«U¡AµL¦×¥O¤H½G¡FµL¦Ì©O¡H¥O¤H®»¨g¡I ¤£¥i«äij¡I¤£¥i«äij¡I
µù¡G 1. 2018/10/23-¤ß®®¬ü°ê±M§Q¡GUS 10,105,378 B2 ¡uENRICHMENT METHODS FOR PREPARING TANNIC ACID COMPOSITIONS.¡v ¸Ì±´£¨ì³\¦h»s³Æ³æ¹ç»Äªº¤è¦¡¡]¬ù11ºØµÑ¨ú¼W¯qªk¡F¦¬¦¨²v¬ù¤¶©ó54¢H-80¢H¶¡¡^»P³æ¹ç»Ä¥Î©ó¤p¹«ºë¯«¯f¼Ò¦¡¤Uªº§ïµ½µ{«×¡C 2. 2008-¡u¶Ç²Î¤¤ÃĨì´Óª«·sÃÄ-¤¤¯óÃÄ·sÃĶ}µo ÃöÁä°ÝÃD»P¤ÀªR¡v¡]www.biotaiwan.org.tw/mag/image_doc/14/08%E7%94%B1%E5%82%B3%E7%B5%B1%E4%B8%AD%E8%97%A5%E5%88%B0%E6%A4%8D%E7%89%A9%E6%96%B0%E8%97%A5---%E4%B8%AD%E8%8D%89%E8%97%A5%E6%96%B0%E8%97%A5%E9%96%8B%E7%99%BC%E7%9A%84%E9%97%9C%E9%8D%B5%E5%95%8F%E9%A1%8C%E8%88%87%E5%88%86%E6%9E%90.pdf ¡^ 3. 2021-¡u«O°·¹«~±`¥Î¤§¤ÀÂ÷¯Â¤Æ¬yµ{¡v¡]www.cie.org.tw/cms/JournalFiles/11012_chapter07.pdf¡^ 4.¡uwww.cych.org.tw/pharm/drugnewsdetail.aspx?msg_id=1514 ¡v 5. 2022/10/21-¡uFDA Releases Much-Anticipated Guidance around Trial Endpoints¡v¡]www.biospace.com/article/fda-releases-much-anticipated-guidance-around-trial-endpoints/¡^ ¸`Ķ¡G¡u¦b¦hÓ¤è±ÃÒ©úÀø®Äªº°ÝÃD³Ì²×¨Ï¦Ê°·¡]Biogen¡^©M½Ã§÷¡]Eisai¡^ªºªü¯÷®üÀq¯fÃĪ«Aduhelm (aducanumab) ¥¢±Ñ¡C ¾¨ºÞ¥¦³Ì²×¦b2021¦~6¤ëÀò±o¤FFDA ªº§åã¡A¦¨¬°¦³¥v¥H¨Ó²Ä¤@Ó³Q§åã¥Î©óªvÀøªü¯÷®üÀq¯gªºÃĪ«¡A¦ý¸ÓÃĪ«¤@ª½¨ü¨ì¼sªxªºÃhºÃ©Mª§Ä³¡C ¸ÓÃĪ«¦b¹ê»Ú¨Ï¥Î¤¤¥¼¯à²£¥Í«Ü¤jªº§l¤Þ¤O¡C4¤ë¡A¸g¹L¤j¬ù10Ӥ몺ª§Ä³¡A¬ü°êÂåÀø«OÀI¤½¥q¹ïAduhelmªº¥Ó³ø®Ö¾P³W«h¥[¥H³]¡A«d®z¤F³oÃijQ¶}¥X³B¤èªº¾÷·|¡C´XÓ¤ë«á¡A¦Ê°·¡]Biogen¡^©M½Ã§÷¡]Eisai¡^¥H¦¬®×²v§C¬°¥Ñ©ñ±ó¤F¸ÓÃĪ«ªº¤W¥««áÆ[¹î¬ã¨s¡C Aduhelm ¥u¹F¼Ð¤F¤@¶µÁ{§ÉÀø®Ä²×ÂI¡A¦ý¨ä¥LÁ{§É²×ÂI«h¥¼¹F¼Ð¡C FDA¦b¶g¥|ªº¥ø·~«ü¤Þ¤å¥ó¤¤¼g¹D¡G¡y³\¦h¯e¯f³£¦³¦hºØ«á¿ò¯g¡A¨ä¤¤¥ô¦ó¤@Ӥ豪º®ÄªG³£¥i¥H¤ä«ù±o¥X¦³®Ä©Êµ²½×¡C¡z ¡y¶È¿ï¾Ü¨ÃÃöª`¨ä¤¤¤@ºØ«á¿ò¯g¬O¤£°÷ªº¡A¦Ó¿ï¾Ü¦hºØ«á¿ò¯gÁöµM¦b¯f²z¤W§ó¦X¾A¡A¦ý¥i¯à·|¦³°ÝÃD¡C¡z¡v
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G²q·Q10148412 |
µoªí®É¶¡:2022/12/5 ¤W¤È 07:05:03
²Ä 1660 ½g¦^À³
|
¤ß®®¬O§_¤w½m´N [ ¶W¯Å¾Ç¦WÃÄ ] ªº»s³Æ¥B§¹¦¨°Êª«ªº¸ÕÅç ? ½²±Ð±Â¤ß¥Ø¤¤ [ ¶W¯Å¾Ç¦WÃÄ ] ªº¯S½è --- ±N²{¦æºZ¾PÃĪ«©M¬Y¨Ç¤Æ¦Xª«µ²¦X , §Î¦¨²{¦æÃĪ«ÆQªº§Î¦¡ , ¨Ã¨ã¦³ .. §ïÅÜìÃĪ«ªºª«²z©Ê½è --- ¼W¥[·»¸Ñ«×©MÃÄ¥N°Ê¤O .. ´î»´©Î®ø«ÚìÃĪ«ªº¥Dn°Æ§@¥Î .. ¶W¶VìÃĪ«ªºÀø®Ä
¯«¸gÃĪ«ªºÆQÃþ¤Î¨ä¥Î³~©Ò´¦¥Üªº¤º®e´N¬O¥¦ªºÃÒ©ú ±N³¡¤À²{¦æºZ¾PÃĪ«¦¨¥\»s³Æ , ¨Ã¦b¹«Åé¸ÕÅçÅã²{¹w´Á®ÄªG ÕY¦b¤HÅ馨¥\½Æ»s , ¨ú¥N²{¦³ÃĪ«¥«³õ©Î¥i´Á«Ý ? ½²±Ð±Âªº³Ð·N¬ãµo©M¥«³õ¶¯¤ß , ȱo³Üªö !
¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a !
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G²q·Q10148412 |
µoªí®É¶¡:2022/12/4 ¤U¤È 03:17:00
²Ä 1659 ½g¦^À³
|
kim¤j ¥h¦~¤U¥b¦~¨ì¤µ¦~¤W¥b¦~¦h¤ä¥X SNB01ªºÁ{§É¶O¥Î ( À³¸Ó¶W¹L 1.5»õ·s¥x¹ô ) ©Ò¥H ( 3.15 + 1.63 - 1.5 ) /3 = 1.1 »õ ( ¥b¦~¥§¡ªá¶O ) 1.5 -1.1 = 0.4»õ µM 8¤ë¨p¶Ò0.21 »õ , ¤S¦³¹w¥I´Ú¶µ¶W¹L 0.9 »õ ©Î³\¯à¦A¼µÓ¤@¨ì¨â©u ?
¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a !
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡Gkim10134548 |
µoªí®É¶¡:2022/12/4 ¤U¤È 02:13:16
²Ä 1658 ½g¦^À³
|
¤ß®® 110¦~ªºÀç·~¶O¥Î¤ä¥X¬°3.15»õ 111¦~¤W¥b¦~Àç·~¶O¥Î¤ä¥X¬°1.63»õ ¦Ó111¦~¤W¥b¦~±b¤W²{ª÷¥u³Ñ¬ù1.5»õ ´«¨¥¤§¡A¨ì¥»¤ë¤½¥qªº²{ª÷´N¿N§¹¡A³sµoÁ~¤ô³£¦³°ÝÃD©O¡H ¦³µL¤F¸Ñªº¥ý¶i¡A¥i¥H¸Ñ´b¤@¤U¡H |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G²q·Q10148412 |
µoªí®É¶¡:2022/11/17 ¤W¤È 05:24:57
²Ä 1657 ½g¦^À³
|
¬°¤ß®®·P¨ì¤£±Ë§r¡I
SND-13¦b¥xÆW¦¬®×¡A¦³¤H¿Ë¦a§Q¤§«K ©Î³\¤½¥q¥i¥H³z¹L¨Ã½Ð¥xÆWºë¯«Âå¾Ç·|À°¦£©Î¥D¨ÆÂå®v¨p¤U½Ð°U ½Ðºë¯«¬ìÂå®v̤¶²Ð±wªÌ¡A¥H§Q¥[³t¦¬®× ²¦³º¥xÆW®³ºë¯«¤Àµõ¯g«¤j¶Ë¯f¥dªº±wªÌ¡A¶W¹L 10¸U¤H Y¤£¹Hªk³W¡A©Î¥i¤@¸Õ¡H «Øij¤½¥q¥D°Ê¥XÀ»
¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a¡I
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡GWalden10140608 |
µoªí®É¶¡:2022/11/8 ¤U¤È 10:33:34
²Ä 1656 ½g¦^À³
|
¬Ý¨º¨Ç¶ÌB·|»{ ªO¹¹Âû±Æ¶R¦n¬Ý¤U¥h |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡GABC10134671 |
µoªí®É¶¡:2022/11/8 ¤U¤È 07:50:33
²Ä 1655 ½g¦^À³
|
¥«»ù¤~27¤¸ ²{ª÷¼W¸ê»ù40 ½Ð°Ý½Ö·|·Q»{ÁÊ 1.¥»¦¸²{ª÷¼W¸êµo¦æ´¶³qªÑ12,000,000ªÑ¡A¨CªÑ±ÃB·s¥x¹ô10¤¸¡A¥H¨CªÑ·s¥x¹ô40¤¸·¸»ùµo¦æ¡A°£¨Ì¤½¥qªk«O¯d10%p1,200,000ªÑ¥Ñû¤u»{ÁÊ¥~¡A¨ä¾l90%p10,800,000ªÑ¥ÑìªÑªF«ö»{ªÑ°ò·Ç¤é¤§ªÑªF¦Wï©Ò¸ü¤§ªÑªF«ùªÑ¤ñ¨Ò»{ÁÊ¡A¨C¥aªÑ¥i»{ÁÊ89.1905423ªÑ¡AìªÑªF»{Áʤ£¨¬¤@ªÑ¤§·î¹sªÑ¡A¥ÑªÑªF¦Û¦æ¨Ö´ê¡CìªÑªF¤Îû¤u©ñ±ó»{Áʤ§ªÑ¥÷©Î¨Ö´ê¤£¨¬¤@ªÑ¤§·î¹sªÑ¡AÀÀ½Ð±ÂÅv¸³¨Æªø¬¢¯S©w¤H«öµo¦æ»ù®æ»{ÁÊ¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G²q·Q10148412 |
µoªí®É¶¡:2022/11/8 ¤U¤È 01:55:19
²Ä 1654 ½g¦^À³
|
<< COVID-19 «á¿ò¯g >> ¬ü°ê°ê¥ß½Ã¥Í¬ã¨s°| NIH : ±N©Û¶Ò 1,700¦Wµû¦ô½÷·ç Paxlovid ªvÀøªø·s«a¼ç¤O www.genetinfo.com/international-news/item/64105.html
¡K ±N±wªÌ¤À°t¨ì¤T¤j¯gª¬¸s --- ¡u¹B°Ê@¨ü©Ê§C¡v ¡B¡u»{ª¾¥\¯à»Ùê¡v ¡B¡u¯«¸g¨t²Î¥\¯à»Ùê¡v ªº¦Ü¤Ö¤@¸s ¹êÅç²Õ±NªA¥Î Paxlovid ¨C¤Ñ¨â¦¸ , «ùÄò15 ¤Ñ ; ¥DnÆ[¹î«ü¼Ð«h¬O³o¨Ç¯gª¬¦b 90 ¤Ñ¤ºªºÅܤƱ¡ªp , ¥Hµû¦ô Paxlovid ¦bªvÀøªø·s«aªº¼ç¤O ¡K
¡u¹B°Ê@¨ü©Ê§C¡v ¡B¡u»{ª¾¥\¯à»Ùê¡v ¡B¡u¯«¸g¨t²Î¥\¯à»Ùê¡v³o¥i¯à²o¯AªÍ¥\¯à ©M ¸£¥\¯à ªº°ÝÃD SNB01 ¤£¬O¤]¦³³o¨Ç¥\¯à¶Ü ? ºû«ùªÍ³¡°·±d¾÷¯à¡BÀ°§Uºû«ù»{ª¾¤Î°O¾Ð¤O ©M ¯«¸g«OÅ@ ?
½²¸³¬O§_¸Ó¥h¦V NIH ª§¨ú , ±NSNB01 ¤]¦C¤JÁ{§Épµe ? Y¥iÃÒ¹êÀø®Ä , ©Î±NÁn¦W¤j¾¸ ?
¶È¨Ñ°Ñ¦Ò ÁÂÁ !
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G²q·Q10148412 |
µoªí®É¶¡:2022/11/5 ¤W¤È 08:34:31
²Ä 1653 ½g¦^À³
|
Tanquilynne «O°·«~¦A§ä¨ì 4 Ó¥i¯à¥\®Ä --- §í§¿»Ä¡BÄáÅ@¸¢ªÎ¤j¡BG¹¹D°f¬y¡BG¼ìºÅ ?
GA ´î¤Ö§¿»Äªº²£¥Í
*** ¯ù¤Î¨ä¦¨¤À³q¹L§í¨î¶ÀáIËï®ñ¤Æ酶´î¤Ö§¿»Äªº²£¥Í www.ncbi.nlm.nih.gov/pmc/articles/PMC9250135/ 2022/06 ¼sªF¬Ù¹A·~¬ì¾Ç°|¯ù¸¬ã¨s©Ò/¼sªF¬Ù¯ù¾ð¸ê·½³Ð·s»P§Q¥Î«ÂI¹êÅç«Ç, ¼s¦{ µØ«n¹A·~¤j¾Ç¶éÃÀ¾Ç°|
¯ùªº°·±d¯q³B¬O¦hºØ¦h¼Ëªº¡A¥]¬A°§C§¿»Ä¤ô¥¡C¶ÀáIËï®ñ¤Æ酶 ( Xanthine oxidase , XOD ) ¬O§¿»Ä²£¥Í¤¤³Ìª½±µ¤¶¾Éªº酶¡C
¦b°ª§¿»Ä¨x²ÓM¼Ò«¬¤¤¨ë¿Eªº¶ÀáIËï®ñ¤Æ酶¬¡©Ê§í¨î©M¶ÀáIËï²æ²B酶mRNAªí¹F¤ô¥ªí©ú¡A¥¼µo»Ãºñ¯ù©M»´«×µo»Ã¶À¯ù¡B¥Õ¯ù©M¯QÀs¯ù©úÅã±j©ó°ª«×µo»Ã¬õ¯ù©M¶Â¯ù¡C¥Dn¥Íª«¬¡©Ê¤Æ¦Xª«¨S¹¤l»Ä¹ï§¿»Ä²£¥Íªº§í¨î§@¥Î³Ì±j¡A¨ä¦¸¬O¯ù¦h×ô©M¯ù¶À¯À¡C
ȱo¤@´£ªº¬O¡A¨S¹¤l»Ä¦b§í¨î§¿»Ä¥Í¦¨¤è±ªí²{¥X«n§@¥Î¡A¬Æ¦ÜÀu©ó¯ù¦h×ô©M¯ù¶À¯À¡C³o¬O¥H«e±q¥¼³Qµo²{©M¤ñ¸û¹Lªº¡C¯ù¡B¯ó²ù¡BÂfÂc¡B¤¿¤l¡Bº£¾ð¡B¾ó¾ð¥Ö©MÄ«ªG¥Ö¤¤ªº¨S¹¤l»Ä¬O¤@ºØ¤ÑµM°·±dªº¤Æ¦Xª« ¡C¡C¦¹¥~¡A¥i±q«p¸¥ÕÍ¿¤¤´£¨úªº¤s¤òõѯÀ¨ã¦³»P¨S¹¤l»Ä¬Û¦Pªº 3,4,5-¤Tßm°òf¥Ò»Äµ²ºc¡A³o¤]³QÃÒ©ú¬O¤@ºØªvÀø°ª§¿»Ä¦å¯gªº·sµ¦²¤¡C¦]¦¹¡A¨S¹¤l»Ä¦b¥¼¨Ó¥i¯à¨ã¦³¶}µo°§¿»Ä§@¥Îªº¥¨¤j¼ç¤O¡C
TA ¹ïBenign prostatic hyperplasia (BPH) --- ÄáÅ@¸¢ªÎ¤j ªº§í¨î§@¥Î
*** Anoctamin 1 (TMEM16A) ¹ïâé଻¤¾Éªº«e¦C¸¢¼W¥Í¦ÜÃö«n www.pnas.org/doi/10.1073/pnas.1423827112 2015/07 Áú°ê¾ÇªÌ
¨}©Ê«e¦C¸¢¼W¥Í (BPH) ªº¯S¼x¬O«e¦C¸¢¦b¸Ñåµ²ºc¤W¼W¤j¡A¬O¦Ñ¦~¨k©Ê³Ì±`¨£ªº¯e¯f¤§¤@ ¡C¶W¹L 50% ªº 60 ·³¥H¤W¨k©Ê±w¦³¤U§¿¸ô¯gª¬¡A¥]¬A§¿ÅCÃÜ¡B§¿¬yµL¤O©M©]§¿¡A³o¨Ç¯gª¬³q±`¥Ñ»H¯Ö±ðªý¤Þ°_ ¡C¤wª¾âé଩ΤG²Bâéଠ(DHT) ªº¥i¥Î©Ê·|¾ÉP²Õ´¾Ç¯S¼x©Ê BPH ªºµo®i ¡C
Anoctamin1 (ANO1¡A¤]ºÙ¬° TMEM16A) ½s½X¤@Ó Ca 2+¿E¬¡ªº´âÂ÷¤l³q¹D (CaCC) ¡A¨Ã¼sªxªí¹F©ó¤Àªc©Ê¤W¥Ö²ÓM¡A¥]¬A³è²G¸¢¡B®ðºÞ ©M¸z¹D¡B¥·Æ¦Ù©M·Pı¯«¸g¤¸¡C¤wª¾ ANO1 ¥i¤¶¾É¦UºØ¥Í²z¥\¯à¡A¨Ò¦pÅé²G©M¹q¸Ñ½è¤Àªc¡B¸z¹Dį°Ê¡B¦åºÞ¥·Æ¦Ù¦¬ÁY©M¼ö¶Ë®`·P¨ü ¡C
ANO1 ¤w³Q»{¬°¬O²ÓM¼W´Þ©M¸~½Fµo¥Íªº½Õ¸`¾¯¡A¬Æ¦Ü¦b¥¦³Qµo²{¬° CaCC ¤§«e¡A¥¦¦b¦hºØÀù¯g¤¤°ª«×ªí¹F¡A¥]¬AG¸z¹D¶¡½è½F ¡B¹ºÞÅ쪬²ÓMÀù ¡BÀYÀV³¡Å쪬²ÓMÀù ¡B¤fµÄÀù ¡B¨Å¸¢Àù ©M«e¦C¸¢Àù ¡CAno1ªº¯}Ãa©Îµ¹¤©ÃIJz¾Ç ANO1 §í¨î¾¯·|·l®` Cajal ¶¡½è²ÓM©M³\¦hÀù²ÓMªº¼W´Þ¡CANO1 ³q¹L»¤¾Éªí¥Ö¥Íªø¦]¤l¨üÅé¿E¬¡ªºµ·µõì¿E¬¡³J¥Õ¿E酶 (MAPK)/AKT «H¸¹¶Ç¾É«P¶i¸~½Fµo¥Í©MÀù¯g¶i®i¡A¨Ã³q¹L ezrin/radixin/moesin ³J¥Õ®a±Ú½Õ¸`¸~½F²ÓM¹B°Ê©MÂಾ¡C¦]¦¹¡AANO1 ³Q»{¬°¬O§ÜÀùªvÀøªº¼ç¦b¹vÂI ¡C
³æ¹ç»Ä§í¨î«e¦C¸¢¼W¤j
§ÚÌÀˬd¤F ANO1 ªº¥\¯à§í¨î¬O§_¥i¥H¦bÅ餺ªýÂ_âé଻¤¾Éªº«e¦C¸¢¼W¤j¡C¬°¤F»¤¾É«e¦C¸¢¼W¤j¡]BPH¼Ò«¬¡^¡A6¶gÄÖ¶¯©Ê¤j¹«³QìI³Î¡AµM«á¥Î¤þ»Äâéଡ]3mg/kg¡A¥Ö¤Uª`®g¡^ªvÀø4¶g¡]¹Ï5A ¡^¡C»P¸üÅéªvÀøªº¥h¶Õ¹ï·Ó²Õ¬Û¤ñ¡AâéପvÀø²Õªº«e¦C¸¢«¶qÅãµÛ¼W¥[¡]¹Ï5B¡^¡C§@¬°¶§©Ê¹ï·Ó¡A5£\-ÁÙì酶§í»s¾¯«D¨º¶¯Ói³Qµ¹¤©¥h¶Õ¶¯©Ê¤j¹«¡Cªø´ÁªA¥Î«D¨º¶¯Ói¡]10 mg/kg¡A¤fªA¡^ÅãµÛ°§C«e¦C¸¢«¶q¡]P < 0.001¡An= 8)¡Aªí©ú«e¦C¸¢¼W¥Íªºµo®i»Ýnâéà¬Âà¤Æ¬° DHT (¹Ï5B )¡CÃþ¦ü¦a¡A·íµ¹¤©³æ¹ç»Ä¡]150mg/kg¡A¤fªA4¶g¡^®É¡A«e¦C¸¢«¶q¤]ÅãµÛ°§C¡]P <0.001¡An =5¡^¡]¹Ï5B¡^¡C
¦³½ìªº¬O¡AANO1 ¦bÅ餺±wªÌªº«e¦C¸¢Àù²ÓM©M«e¦C¸¢¸¢Àù¤¤¤]°ª«×ªí¹F ¡C¦]¦¹¡AµL½× BPH »P«e¦C¸¢Àù¤§¶¡ªºÃöÁp¦p¦ó¡AANO1 ¦b«e¦C¸¢¼W¥Í©MÀù²ÓM¤¤§¡¦³ªí¹F ¡C¦]¬°¥¦Ì¹ï¦ü¥G½Õ¸` ANO1 ªí¹Fªº¶¯¿E¯À±Ó·P¡A©Ò¥H²@¤£©_©Ç¦aµo²{ ANO1 ªº¤ô¥¦b³o¨âºØ¯e¯f¤¤³£³Q¤W½Õ¡C¦¹¥~¡AANO1 ªí¹Fªº§í¨î°§C¤F¤HÃþ«e¦C¸¢Àù¤¤ªº¸~½F¥Íªø©M«Iŧ©Ê¥H¤Î BPH ¼Ò«¬¤¤«e¦C¸¢ªº¤j¤p ¡C¦]¦¹¡AANO1 ¥i¯à¦b BPH ©M«e¦C¸¢Àùªº¶i®i¤¤°_ÃöÁä§@¥Î¡C
GA ¹ï G¹¹D°f¬yªº«OÅ@
*** Ameliorative and antioxidant effects of myrtle berry seed ( Myrtus communis ) extract during reflux-induced esophagitis in rats ®çª÷Ä]ºØ¤l¡]®çª÷Ä]¡^´£¨úª«¹ï¤j¹«¤Ï¬y©Ê¹ºÞª¢ªº§ïµ½©M§Ü®ñ¤Æ§@¥Î www.tandfonline.com/doi/full/10.3109/13880209.2015.1107748 2015
¹¹D°f¬y¡]ER¡^
ªí2 GA ªº«OÅ@²v 69.56 % ( ¤fªA 50 mg/kg )
§ÜG¼ìºÅ
*** TA ¬O¤@ºØ¤ñÂýªá»Ä§ó¦³®ÄªºG H +¡BK + -ATP 酶§í»s¾¯¡A¨ÃÅãµÛ§í¨îG»Ä¤Àªc©M¼ìºÅµo¥Í pubs.acs.org/doi/pdf/10.1021/np50082a022 1992
*** ¨S¹¤l»Ä¹ï¤j¹«ªº§Ü¼ìºÅ§@¥Î¤Î¨ä¹ïG²Õ´®ñ¤Æ©M§Ü®ñ¤Æ°Ñ¼Æªº¼vÅT www.ncbi.nlm.nih.gov/pmc/articles/PMC3757852/ 2013 ¦L«×¾ÇªÌ
¦b¥»¬ã¨s¤¤¡A§Ú̬ã¨s¤F¨S¹¤l»Ä¹ïªü¥q¤ÇªLÁp¦X pyrolus µ²²Ï»¤¾Éªº¤j¹«G¼ìºÅªº§Ü¼ìºÅ§@¥Î¡C¤j¹«¥Î¨S¹¤l»Ä¡]100 ©M 200 mg/kg¡^©Mªk²ö´À¤B¡]20 mg/kg¡^³B²z 1 ¶g¡AµM«á¨Ï¥Îªü¥q¤ÇªL¥[ pyrolus µ²²Ï¼Ò«¬»¤¾ÉG¼ìºÅ¡C
¾¯¶q¬°100©M200mg / kgªº¨S¹¤l»Ä¤À§Oµo´§69.7%©M78.9%ªº¼ìºÅ§í¨î§@¥Î¡C¶W®ñ¤Æª«ª[¤Æ酶¡B¹L®ñ¤Æ²B酶¡BÁÙ쫬¨¦¯Ö¥Ì肽¡B½\¯Ö¥Ì肽ÁÙì酶¡B½\¯Ö¥Ì肽¹L®ñ¤Æª«¡B¸²µå¿}-6-ÁC»Ä²æ²B酶¤ô·Ç¤É°ª¡A¦P®É¦bÃĪ«ªvÀø¤j¹«G²Õ´¤¤Æ[¹î¨ìÅè¹L®ñ¤Æª«酶©M¯×½è¹L®ñ¤Æ´î¤Ö¡C²Õ´¯f²z¾Ç¬ã¨s¶i¤@¨BÃÒ¹ê¤F¨S¹¤l»Äªº§Ü¼ìºÅ¬¡©Ê¡C§Ú̱o¥Xµ²½×¡A¨S¹¤l»Ä¨ã¦³§Ü¼ìºÅ§@¥Î¡A¨Ã¥B³o¨Ç§@¥Î¬O³q¹L¤@ºØ¾÷¨îµo¥Íªº¡A¸Ó¾÷¨î¯A¤Î´î®z§ðÀ»¦]¯À¡A³q¹L±Ò°Ê§Ü®ñ¤Æ°Ñ¼Æ¨Ó§ïµ½Öß½¤¨¾¿m©M§í¨î¤@¨Ç¦³¬rªº®ñ¤Æ¾¯°Ñ¼Æ¡C
¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a !
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G²q·Q10148412 |
µoªí®É¶¡:2022/11/4 ¤U¤È 03:52:23
²Ä 1652 ½g¦^À³
|
¨Ó¦ÛªB¤Íªº¤À¨É
SARS-CoV-2 ¬OPÀù¯f¬r¶Ü¡H www.journalofinfection.com/article/S0163-4453(22)00469-8/fulltext
§ÚÌÀˬd¤F¤TÓ°ò¦]ªí¹F¼Æ¾Ú¶°¡A¥HÃÒ©ú p53 ¦b«æ©Ê SARS-CoV-2 ·P¬V©Mªø´Á«aª¬¯f¬r¯f 19 (COVID-19) ´Á¶¡³Q¤U½Õ¡Fp53 ªºªø´Á°§C¥i¥H¸ÑÄÀ¬°PÀùªº¦MÀI¦]¯À¡C
¤T½g½×¤å¨Ñ°Ñ
*** ³æ¹ç»Ä¡B¥ÕòÔĪ¾J¤Î¨äl¥Íª«¹ï¤H¤¤©Ê²É²ÓM®ñ¤Æ·l¶Ë©Mä¤`ªº¼vÅT www.sciencedirect.com/science/article/abs/pii/S0278691515300211
¦h×ô¡B³æ¹ç»Ä©M芪¦bÀR®§ªº¤H¤¤©Ê²É²ÓM¤¤µo´§«P®ñ¤Æ§@¥Î¡A¨Ã¦ñ¦³ p53 »¤¾É
*** ³æ¹ç»Ä§í¨î Jak2/STAT3 ³q¸ô¨Ã»¤¾É YD-38 ¤úÅiÀù²ÓM G1/S ´Áªýº¢©M½u²ÉÅéä¤` www.spandidos-publications.com/10.3892/ijo.2015.3098
TA §í¨î G1 ´Á½Õ¸`¾¯ CDK-4¡BCDK-6¡Bcyclin D1 ©M cyclin E ªºªí¹F¡CÁÙÃÒ©ú TA ±j¯P¿E¬¡ p21Waf1/Cip1¡Bp27Kip1 ©M p53 °ò¦]¡AÃÒ¹ê¤F¨ä¦b G1 ´Á§í¨î¤¤ªº§@¥Î¡C
*** Upregulation of p53 by tannic acid treatment suppresses the proliferation of human colorectal carcinoma ³æ¹ç»ÄªvÀø¤W½Õp53 , §í¨î¤Hµ²ª½¸zÀù¼W´Þ hrcak.srce.hr/file/356920
¤T´Á P53 ¥i¥H¦C¬°Æ[¹î«ü¼Ð¶Ü ?
¶È¨Ñ°Ñ¦Ò ÁÂÁ !
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G²q·Q10148412 |
µoªí®É¶¡:2022/11/2 ¤W¤È 08:40:15
²Ä 1651 ½g¦^À³
|
¸É¥R --- ¹ï°ª¦åÀ£ ¡B¿}§¿¯f¤j¹«EDªº¸ÕÅç , ÁÙ¦³±M®aÆ[ÂI
°ª¦åÀ£¤j¹«ªº ED
*** ÁC»Ä¤Gà酶 5 §í¨î¨ó¦P rho ¿E酶«ú§Ü§@¥Î¨Ã¼W±j¶¯©Ê°ª¦åÀ£¤j¹«ªº«k°_¤ÏÀ³ www.nature.com/articles/3901149 2004/04 ¬ü°ê¥[§QºÖ¥§¨È¤j¾Ç¸t¦a¨ÈôÂå¾Ç¤¤¤ßªc§¿¥~¬ì
¬°¤Fµû¦ô°ª¦åÀ£¡B¨k©Ê«k°_¥\¯à¡BRho ¿E酶©M´`Àô GMP ³q¸ô¤§¶¡ªºÃöÁp¡A§Ú̺ʴú¤F¦Ûµo©Ê°ª¦åÀ£ (SHR)»P¦åÀ£¥¿±`ªº¤j¹«¡C§ÚÌÁÙµû¦ô¤F®üºøÅ餺µù®g¯S©w Rho ¿E酶§í¨î¾¯ Y-27632 ©Î Y-27632 ©M PDE5 §í¨î¾¯ zaprinast ªº²Õ¦X¥H¨¾¤î cGMP °¸Ñ¤§«e©M¤§«áªº SHR «k°_¥\¯à¡C»P¥¿±`¦åÀ£¤j¹«¬Û¤ñ¡ASHR ¨ã¦³¸û§CªºÀR®§°ò½u®üºøÅéÀ£¤O©M¸û°ªªº¸~µÈµo®iìHÈ¡C¦b SHR ¤¤¡AY-27632 µ¹ÃÄ°fÂà¤F¨k©Ê«k°_¥\¯à¤¤»P°ª¦åÀ£¬ÛÃöªºÅܤơFRho ¿E酶«ú§Ü©M PDE5 §í¨îÁp¦X¨Ï¥Î¦b§ïµ½¯«¸g·½©Ê«k°_¤ÏÀ³¤è±¨ã¦³¨ó¦P§@¥Î¡C§Ú̪º¼Æ¾Úªí©ú¡A°ª¦åÀ£»P SHR ¯«¸g·½©Ê«k°_¤ÏÀ³¨ü·l¦³Ãö¡A³o¥i¯à¯A¤Î³±²ô«k°_²Õ´¤¤¦å¬y°Ê¤O¾Ç¾÷¨îªº¯¿¶Ã¡C
¿}§¿¯f°Êª«ªº ED
*** Rho ¿E酶§í¨î¾¯ SAR407899 ¦b¿}§¿¯f°Êª«©M¤HÃþ¤ÀÂ÷ªº®üºøÅ餤ªº«k°_¯S©Ê translational-medicine.biomedcentral.com/articles/10.1186/1479-5876-10-59 2012/03 Sanofi-Midy ¬ã¨s¤¤¤ß¡A±´¯Á³æ¦ì¡AÁÉ¿Õµá¬ãµo¡AVia G. Sbodio 2¡A¦ÌÄõ¡A·N¤j§Q
¬y¦æ¯f¾Ç¬ã¨sªí©ú¡A¤j¬ù 50% ªº 40 ¦Ü 70 ·³¨k©Ê±w¦³¬YºØµ{«×ªº«k°_¥\¯à»Ùê (ED)¡A³o³q±`»P°·±dª¬ªp¤£¨Î©ÎºC©Ê¯e¯f¦³Ãö¡A¨Ò¦p°Ê¯ßµ°¼Ëµw¤Æ¡B¿}§¿¯f¡B§íÆ{¯g©M©Ê¸¢¾÷¯à´î°h ¡CED ¤]¥i¯à¥Ñ½Ñ¦p§Ü§íÆ{ÃÄ¡B§Ü°ª¦åÀ£ÃÄ¡B¯f¬r³J¥Õ酶§í»s¾¯©M§Ü¯uµß¾¯µ¥ÃĪ«»¤µo¡A©ÎªÌ¸û¤Ö¨£ªº¥Ñ·l®`³±²ô°Ê¯ß¨ÑÀ³©Î¯áÅè¥\¯àªºª«²z³Ð¶Ë¤Þ°_ ¡C
RhoA-Rho ¿E酶½Æ¦Xª«¦³§U©ó«O«ù®üºøÅ饷Ʀ٦¬ÁY¡A¨ä§í¨î³Q»{¬°¬OªvÀø«k°_¥\¯à»Ùê (ED) ªº¼ç¦bµ¦²¤
§Ṳ́ñ¸û¤F SAR407899¡BRho ¿E酶§í¨î¾¯ Y-27632 ©M PDE5 §í¨î¾¯¦è¦a¨º«D¦b°·±d©M¿}§¿¯f°Êª«¤¤©ñÃP»P¥h®ñµÇ¤W¸¢¯À¦¬ÁYªº®üºøÅé±aªº¯à¤O¡C
SAR407899 ¾¯¶q¨Ì¿à©Ê¦a©ñÃP©Ò¦³ª«ºØªº¹w¦¬ÁY®üºøÅé , »P¦è¦a¨º«D¤£¦P¡ASAR407899 ¹ï³±²ô«k°_ªº»¤¾É¦b«Ü¤jµ{«×¤W»P e-NO ¬¡©ÊµLÃö¡C³oªí©ú¥¦¥i¥Î©óªvÀø e-NO ¬¡©Ê¨ü·lªº¿}§¿¯f©M°ª¦åÀ£±wªÌªº«k°_¥\¯à»Ùê¡C
±M®aÆ[ÂI --- PDE5©MROCK§í¨î¾¯ªºÁp¦X , ®ÄªG¥i¯à§ó¦n ?
*** Too much ROCK ¡X erection block www.nature.com/articles/nrurol.2016.231.pdf?origin=ppub
¡§¦b³o¶µ¬ã¨s¤¤¡A§Ú̺¦¸±NROCKªí¹Fªºµ²ªG»P¤HÃþÀô¹Ò¤¤ªº¥\¯à¼Æ¾Ú¬Ûµ²¦X¡AÃÒ¹êROCK¥i¯à¬OEDªvÀøªº¤@Ó¦³½ìªº¹v¼Ð¡A¡¨Albersen§i¶DNature Reviews Urology¡C¡§¥¿¦b¶}µo´XºØROCK§í»s¾¯¡A¥Î©ó°ª¦åÀ£µ¥¾AÀ³¯g¡CROCK2-¿ï¾Ü©Ê§í¨î¾¯¥i¯à¹ïED§ó¦³®Ä¡A¨Ã¥B²æ¹v®ÄÀ³§ó¤Ö¡APDE5©MROCK§í¨îªº²Õ¦X¥i¯à´î¤Ö¾¯¶q¨Ã¼W±j³±²ô®ÄªG¡C
¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a !
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G²q·Q10148412 |
µoªí®É¶¡:2022/11/2 ¤W¤È 06:58:04
²Ä 1650 ½g¦^À³
|
ªB¤Í¤]¾ã²z ¤@Ó¦³½ìªº¥i¯à¥\¯à , Y¿@«×¥i¥H¹F¨ì¤ô·Ç , »¡¤£©w·|¦³ªþ¥[ªº½æÂI ?
¤µ¤Ñ¨Ó¤@¹D¯S§Oªºµæ¦â ? ¬°¥D¦¨¤À¦PÄݳæ¹ç»Äªº Tanquilynne ( SND-51 ¡B«O°·«~ ) ¤ÎPentarlandir ( SNB01 ) §ä§Q°ò ?
¤j®aÅ¥¹L PDE5 ( phosphodiesterase type 5 , 5 «¬ÁC»Ä¤Gà酶 ) §í¨î¾¯¶Ü ? ÁÙ¦³ ROCK-II ( Rho-kinase 2 , Rho ¿E酶 2 ) §í¨î¾¯ ?
¸q¤j§Q¾ÇªÌ¦b2020¦~Ò¾É PDE5§í¨î¾¯§@¬°COVID-19ªºªvÀøÃĪ«
Targeting the NO-cGMP-PDE5 pathway in COVID-19 infection. The DEDALO project onlinelibrary.wiley.com/doi/full/10.1111/andr.12837
³\¦hÁ{§É©M¹êÅç¬ã¨sªí©ú¡A¤@®ñ¤Æ´á (NO)-Àô GMP-5 «¬ÁC»Ä¤Gà酶 (PDE5) ³q¸ô¦b½Õ¸`¥NÁ¯e¯f±wªÌªº§C«×ª¢¯g¤¤µo´§§@¥Î¡A´£¨Ñ¤ß¦åºÞ«OÅ@¡CPDE5 §í¨î³q¹L½Õ¸`¬¡¤Æªº T ²ÓM¡B´î¤Ö²ÓM¦]¤lÄÀ©ñ¡B°§CÅÖºû¤Æ¡B¼W¥[®ñÂX´²¡B¨ë¿E¦åºÞ×´_¨Ó«P¦¨§Üª¢¤ÏÀ³¡CPDE5 ¦bªÍ³¡°ª«×ªí¹F¡A¨ä§í¨î¥i§ïµ½ªÍÅÖºû¤Æ¡A³o¬OÄY« COVID-19 ¯e¯fªº¨Öµo¯g¡C
¼f¬dªºÃÒ¾Úªí©ú¡APDE5 §í¨î¾¯¥i¥H³q¹L (i) ©è®ø Ang-II ¤¶¾Éªº AT-1 ¨üÅé¤U½Õ¨Ó´£¨ÑºÞ²z COVID-19 ªº·sµ¦²¤¡F(ii) §@¥Î©ó³æ®Ö²ÓMÂà´«¡A±q¦Ó´î¤Ö«Pª¢²ÓM¦]¤l¡B¶¡½è®û¼í©M¾ÉPªÍªw¥X¦åÃa¦ºªº¦åºÞ·l¶Ë¡F(iii) §í¨îªÍ°Ê¯ß¤º¥Ö²ÓM©M¥·Æ¦Ù²ÓM¦V¶¡¥R½è²ÓMªºÂàÅÜ¡A¨¾¤î¾®¦å©M¦å®ê§Î¦¨¨Öµo¯g¡C
¨Ï¥Î PDE5i ³q¹L NO-cGMP ³~®|§ïµ½¤º¥Ö¥\¯à¥i¥HÀ°§U×´_ªÍªw - ¦åºÞ¬É±·l¶Ë¡A±q¦Ó§ïµ½ O2 ÂX´²
¦Ó
TA ¹ï©ó§í¨îPhosphodiesterase PDE5 enzymeªº IC50 = 4,703 nM www.guidetopharmacology.org/GRAC/LigandActivityRangeVisForward?ligandId=4319 ³o¬O¹ï COVID-19 ªvÀøªºªþ¥[¥\¥Î ¦ý³o¤£¬O¤µ¤Ñªº¥DÃD §ÚÌn½Íªº¬O PDE5 §í¨î¾¯ªº¥tºØ¥\¯à ³o¬O¸q¤j§Q¦ÌÄõ¤j¾Ç , ÁÙ¦³^¡B¬ü½÷·ç¤½¥q¦@¦Pªº¬ã¨s
*** ¥Î©óªvÀø«k°_¥\¯à»Ùꪺ 5 «¬ÁC»Ä¤Gà酶§í¨î¾¯¡G¬eòX»Ä¦è¦a¨º«D¤fµÄ¤À´²¤ù»s¾¯ªºÃIJz¾Ç©MÁ{§É¼vÅT pubmed.ncbi.nlm.nih.gov/28139291/ 2017/02
®Ú¾Ú¤wµoªíªº¤åÄm¡APDE5 §í¨î¾¯³Q»{¬°¬OªvÀø ED ( «k°_¥\¯à»Ùê ) ªº¤@ºØ¦³®Ä¥B@¨ü©Ê¨}¦nªº¿ï¾Ü
*** ¤fªAÁC»Ä¤Gà酶 5 §í»s¾¯©M¿E¯ÀªvÀø«k°_¥\¯à»Ùê¡G¨t²Îµû»ù©MîPµÑ¤ÀªR pubmed.ncbi.nlm.nih.gov/19884626/ 2009 ´ì¤ÓµØ¤j¾Ç´ì¤ÓµØ°·±d¬ã¨s©Ò¡A¥[®³¤j¦w¤j²¤¬Ù´ì¤ÓµØ
¼Æ¾Ú¦X¦¨¡G ¥Dn¨Ó¦Ûµu´Á¸ÕÅç¡]<©Î=12 ¶g¡^ªº¼Æ¾Úªí©ú¡APDE-5 §í¨î¾¯¦b´£°ª©Ê¥æ¦¨¥\²v¤è±¤ñ¦w¼¢¾¯§ó¦³®Ä¡]69.0% ¹ï 35.0%¡^¡C±µ¨ü PDE-5 §í¨î¾¯ªvÀøªº¨k©Ê«k°_§ïµ½ªº¤ñ¨Ò¡]½d³ò¡A67.0% ¦Ü 89.0%¡^©úÅã°ª©ó¦w¼¢¾¯¡]½d³ò¡A27.0% ¦Ü 35.0%¡^¡C»P¦w¼¢¾¯¬Û¤ñ¡APDE-5 §í¨î¾¯»P¥ô¦ó¤£¨}¨Æ¥óªº·ÀI¼W¥[¬ÛÃö¡]¨Ò¦p¡A¦è¦a¨º«Dªº¬Û¹ï·ÀI¬° 1.72 [95% CI¡A1.53 ¦Ü 1.93]¡^¡C
µ²½×¡G ¤fªA PDE-5 §í¨î¾¯¥i§ïµ½«k°_¥\¯à¡A¨Ã¨ã¦³¬Û¦üªºÀø®Ä©M¦w¥þ©Ê¡C
¥t¥~ , ÁÙ¦³ ROCK-II ( Rho-kinase 2 , Rho ¿E酶 2 ) §í¨î¾¯
*** ¿z¿ï¥Î©óªvÀø«k°_¥\¯à»Ùꪺ¦L«×ÃĥδӪ«ªº Rho ¿E酶 2 ( ROCK-II ) §í¨î¼ç¤O www.sciencedirect.com/science/article/abs/pii/S0378874112005958?via%3Dihub 2012
®üºøÅ饷Ʀ٠(CCSM) ©M³±²ô°Ê¯ßªºÃP¦¢¾ÉP¦å²Gº¢¯d¦b³±²ô¤¤¡A¾ÉP®üºøÅ餺À£ (ICP) ¤É°ª¡Aªí²{¬°³±²ô«k°_ (Andersson ©M Stief, 1997)¡C¨ü·lªº¤º¥Ö¥\¯à»Ùê¾ÉPÃP¦¢¨ü·l¡A¨Ã¥B¬O ED ªº¥Dnì¦]¡]Maas µ¥¡A2002¡^¡C µo²{ Rho ¿E酶 2 (ROCK-II) §í¨î¾¯ Y-27632¦bÅé¥~¥i©ñÃP¨ß©M¤H®üºøÅé¡]Rees µ¥¡A2001¡^¡C¦¹¥~¡AY-27632 ®üºøÅ餺µ¹ÃÄ·|¼W¥[¦Ñ¦~¤j¹«ªº ICP¡A³o¬O«k°_¥\¯à¼W±jªºªí²{¡]Gao µ¥¤H¡A2007¡^¡C
*** Rho ¿E酶 (ROCK) §í¨î¾¯¤Î¨äªvÀø¼ç¤O pubs.acs.org/doi/abs/10.1021/acs.jmedchem.5b00683 2015/10 ´µ§J¨½´¶´µ¬ã¨s©Ò¡A¦òù¨½¹F¦{
Rho ¿E酶 (ROCKs) ÄÝ©óµ·®ò»Ä-Ĭ®ò»Ä®a±Ú¡A¨ä§í¨î·|¼vÅT³\¦h¤U´å©³ª«ªº¥\¯à¡C¦]¦¹¡AROCK §í¨î¾¯¦b¥]¬Aý³Ý¡BÀù¯g¡B«k°_¥\¯à»Ùê¡B«C¥ú²´¡B¯Ø®q¯À©è§Ü¡BµÇ°IºÜ¡B¯«¸g¤¸ÅÜ©Ê©M°©½è²¨ÃP¯g¦b¤ºªº¦hºØ¯f²zª¬ªp¤¤¨ã¦³¼ç¦bªºªvÀø¾A¥Î©Ê¡C¨´¤µ¬°¤î¡A¨âºØ ROCK §í¨î¾¯¤w¦b¤é¥»Àò§åÁ{§É¨Ï¥Î¡]ªkµÎ¦aº¸©M§Q©¬µÎ¦aº¸¡^¡A¤@ºØ¦b¤¤°êÀò§å¡]ªkµÎ¦aº¸¡^¡C1995 ¦~ªkµÎ¦aº¸³Q§åã¥Î©óªvÀø¸£¦åºÞµjÅË¡A³Ìªñ¡A§Q©¬µÎ¦aº¸©ó 2014 ¦~³Q§åã¥Î©óªvÀø«C¥ú²´¡C
GA §í¨î ROCK ¬¡©Ê
*** ¨S¹¤l»Ä³q¹L§í¨î¼W¥Í©Ê½I²ª¦¨ÅÖºû²ÓM¤¤ªº RhoA/Rho-¿E酶³~®|´î®z TGF-£]1 ¨ë¿Eªº½¦ì¾®½¦¦¬ÁY www.sciencedirect.com/science/article/abs/pii/S0024320516304210?via%3Dihub 2016/09 °ê¥ß¤¤¿³¤j¾Ç¡A¥x¤¤¡A¥xÆW ¥xÆW¥x¤¤¥«¥x¤¤ºa¥ÁÁ`Âå°|±Ð¨|»P¬ã¨s³¡ ¥xÆW¥x¤¤¤¤¤sÂå¬ì¤j¾ÇÂå¾Ç¬ã¨s©Ò ¥xÆW¥x¤¤¤¤¤sÂå¬ì¤j¾ÇÂå°|Âå¾Ç¬ã¨s³¡ ¥xÆW¥x¤¤ºaÁ`Âå°|¥~¬ì¾ã§Î¥~¬ì
ÀHµÛ GA ¹w³B²z©M TGF-£]1 ¨ë¿E¡ARhoA ªº¿E¬¡©Mªí¹F§¡©úÅã¤U°¡C¦¹¥~¡AGA §í¨î ROCK ¬¡©Ê¡A¦ý¦b TGF-£]1 ¨ë¿E«á¤£¼vÅT¨äªí¹F¡C ·N¸q ³o¨Çµ²ªGªí©ú¡AGA ³q¹L¤U½Õ RhoA/ROCK «H¸¹¯ÅÁp¡AÀH«á§í¨î £\-SMA ªºªí¹F¡BF-¦Ù°Ê³J¥Õªº§Î¦¨©M MLC ªºÁC»Ä¤Æ¡Aªí²{¥X¦b TGF-£]1 ¨ë¿E¦Z¨¾¤î HSF ¦¬ÁYªº¼ç¤O¡C
¥i±¤ªº¬O , ¨S¦³IC50ªº¸ê®Æ
Á{®É¥[ºt
*** ¦¬ªªºì¦]¤Î¨äªü¨|§pªûªvÀø¡I www.lybrate.com/topic/causes-of-premature-ejaculation-and-its-ayurvedic-treatment/9eaad0b35459338f86162e4039dfdd01
¼f®Ö¤H Jeevan Sampat Jadhav ³Õ¤h ªü¨|§pªûÂå¾Ç»P¥~¬ì¾Ç¤h (BAMS) ªü¨|§pªûÂå¥Í¡ANashik • 13 ¦~¸gÅç
¥H¤U¬O¤@¨ÇªvÀø¦¬ªªºªü¨|§pªû¦¨¤À ( ¥i±¤¨S¦³½×¤å¸ê®Æ ) ¡K 3. Semal museli (Salmalia Malabarica)¡G¥¦¬O¤@ºØ¯ó¥»´Óª«¡A¨ä´£¨úª«§t¦³³æ¹ç»Ä©M¨S¹¤l»Ä§@¬°¬¡©Ê¤Æ¾Çª«½è¡C ¡K
¥H¤W½×ÂI ·|¤£·|¼W¥[Tanquilynne ( SND-51 ¡B«O°·«~ ) ¤ÎPentarlandir ( SNB01 ) ªº½æÂI©O ?
¶È¨Ñ°Ñ¦Ò ÁÂÁ !
|
|
¡@ |
¦^°Q½×°Ï1¶ |
³Ì·s100«h¦^ÂÐ >> |